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iPSC-derived cardiomyocytes (iPSC-CMs) are a potentially advantageous 
platform for drug screening because they provide a renewable source of 
human cardiomyocytes and can be patient specific. One obstacle to their 
implementation is their neonatal-like electrophysiology, which reduces 
relevance to adult arrhythmogenesis. One method to address this problem is 
to electrically mimic deficient currents in iPSC-CMs using a technique called 
dynamic clamp. Mimicking the missing inward rectifying potassium current, IK1, 
in iPSC-CMs via dynamic clamp pushes action potential characteristics to 
resemble more closely an adult cardiomyocyte. However, this method is 
technically challenging and low throughput, limiting its practical uses for more 
high-throughput applications, such as large-scale drug screening. To address 
this, we aim to create an optically-controlled version of dynamic clamp, which 
because of its contactless nature, could be high-throughput and not limited to 
a single-cell format.  
 
The ideal platform would use optogenetics to supplement the deficient current 
and use a fluorescent voltage indicator to measure the membrane potential. 
Optogenetic tools are commonly used statically and to either stimulate or 
 
 
cease electrical activity. This thesis presents a proof of principle of using 
optogenetic tools in lieu of an electrode by developing an optical dynamic 
clamp (ODC) platform that uses an LED to dynamically activate a 
hyperpolarizing opsin, ArchT, to generate an IK1-like current. This ODC 
platform was verified with the standard electrode-based dynamic clamp (EDC) 
and gave a similar output, demonstrating a proof-of-concept that optogenetics 
are able to mimic an electrode. The ODC platform was challenged with E-
4031, bayK 8664, terfenadine, and verapamil.  The ODC platform was able to 
detect effects of the drugs on action potential characteristics similar to EDC, 
but the ODC platform did not consistently yield results identical to EDC. 
Possible reasons and limitations are discussed. With further development, the 
ODC platform can possibly be refined to be more precise, but maturation of 
iPSC-CMs may still be needed to make the platform more relevant to adult 
electrophysiology. The ODC platform has the potential to expand on the 
possibilities of dynamic clamp by enabling more relevant formats, such as 
monolayers, co-cultures or with other engineered platforms. 
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CHAPTER ONE 
 
BACKGROUND 
 
1.1 Introduction  
 
The goal of drug discovery is to develop a drug to correct an underlying cause 
of some disease pathology by altering a specific pathway, but off-target effects 
can be lethal. Prior to a first-in-human trial, researchers extrapolate results from 
in vitro and in vivo models to predict whether a therapeutic is safe and effective. 
Unfortunately, our current assays can only predict about 80% of cardiovascular 
toxicity seen in clinical trials [1]. Signs of adverse cardiac events in the clinic 
typically present as arrhythmias, myocardial infarction, congestive heart failure, 
and coronary heart disease. In addition, cardiovascular toxicity is one of the 
greatest causes of drug attrition [2]: it is one of the main reasons for project or 
clinical trial termination [1] and 45% of drugs withdrawn from the market from 
1975-2007 were due to cardiac toxicity [3] (Figure 1.1). False negatives put 
patients at risk while false positives prevent the development of potentially 
Figure 1.1: Percent of drugs that were stopped during different phases of drug 
development or withdrawn from the market due to cardiovascular toxicity.  
Adapted with permission from Ref [1].   
ADRs = Adverse Drug Reactions; CDs = Candidate Drugs 
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effective therapeutics. This is further discussed in Section 1.2. The lack of 
translation from pre-clinical models to the human population points to a huge 
unmet need for more sensitive and specific predictive models that better 
recapitulate human biology.  
 
The lack of translation from in vivo safety and efficacy experiments to clinical 
outcome could be largely attributed to the irrelevance of non-human models that 
are typically used in experiments to recapitulate human biology [1], [4], [5]. With 
the advent of human-derived induced pluripotent stem cell (iPSC)-derived cell 
types, it is now possible to study human cells, which can even be directly derived 
from patients. By forcing expression of the Yamanaka reprogramming factors, 
researchers can reprogram adult tissue into pluripotent stem cells and 
differentiate them into a desired cell type [6]. This revolutionary technology 
overcomes many research hurdles: first, providing an ethical and unlimited 
resource of human cells that are difficult to obtain, such as cardiomyocytes, and 
second, generating an in vitro model that is genetically identical to a patient of 
interest. iPSC-CMs would benefit pre-clinical research by providing an easily-
accessible human in vitro model for experimental studies. As an additional 
benefit, patient-derived iPSC-CMs can recapitulate the patient’s disease 
pathology, which is especially advantageous for rare and orphan diseases. 
Patient-derived iPSC-CMs are useful to assess the efficacy of a drug to treat 
that disease or identify potential toxic side effects in potentially vulnerable 
patient populations.  
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The literature is replete with evidence that patient-specific iPSC-derived tissues 
possess a similar pathology to those characterized in patients and they respond 
predictably to well-characterized drugs [7]–[19]. For example, iPSC-CMs 
derived from LQTS2 patients treated with the currently available therapeutics, 
nifedipine, pinacidil and ranolazine, demonstrated that these drugs rescued the 
aberrant electrophysiological phenotype and could be beneficial for LQTS2 
patients [7]. Another example is that iPSC-CMs from patients with Pompe 
disease recapitulated the glycogen accumulation phenotype and treatment with 
L-carnitine improved bioenergetic markers [8]. With this technology, 
researchers have access to patient-specific models that they can fully 
manipulate to thoroughly test hypotheses that would be impossible to test in 
patients. However, the great potential of this technology is limited by the inability 
to differentiate these iPSCs into organized and mature adult tissue. With iPSC-
derived tissues, including iPSC-derived cardiomyocytes (iPSC-CMs), being 
phenotypically stuck in a more fetal-like state, there are limitations to using them 
to reflect adult human behavior. Despite the immature nature of iPSC-CMs, 
these cells are still an attractive in vitro model due to the difficulty of obtaining 
human adult cardiomyocytes. A greater dissection of the chemical and physical 
signals that program a pluripotent stem cell to become a structurally and 
functionally mature cardiac tissue would be needed to produce fully mature 
cells.  
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One approach to addressing the electrical immaturity of iPSC-derived 
cardiomyocytes (iPSC-CMs) is to use a powerful electrophysiological tool, 
dynamic clamp. Dynamic clamp can be used to supplement deficient currents 
in iPSC-CMs to make iPSC-CMs appear electrically mature in order to provide 
results that resemble adult behavior, rather than fetal cardiomyocytes [20]–[22]. 
This technique will be further described in detail in Section 1.5. Particular focus 
will be given to the inward rectifier potassium current (IK1) in this thesis. We are 
developing an optically-controlled platform based on the principles of dynamic 
clamp and designed to use iPSC-CMs with application for drug screening. The 
optical dynamic clamp (ODC) system aims to overcome the technical difficulty 
of obtaining a whole-cell patch to enable high-throughput use of dynamic clamp 
and improve the biological relevance of iPSC-CMs to human adult cardiac 
electrophysiology.  
 
The idealized version of the ODC system would use optical tools to replace the 
function of an electrode: to generate a specified current and to report the 
membrane potential. Optogenetic tools have been used to generate an 
unspecified and static current, but this level of control is inadequate for the 
purposes of dynamic clamp, which will be further explained in Section 1.5. 
Chapter 2 will demonstrate how we are able to control the optogenetic tool, 
ArchT, and mimic the missing biological current IK1 in iPSC-CMs. This provides 
a proof-of-concept of using optogenetics to dynamically generate a current and 
to realize the ODC platform. After establishing the first iteration of the ODC 
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platform, Chapter 3 will explore the practical application of the ODC platform for 
drug screening in single cells by using well-characterized ion channel 
modulators to investigate how the ODC platform performs compared to the 
standard dynamic clamp platform. Chapter 4 will describe the limitations and 
future directions of the ODC system.  
 
1.2 The need for more predictive cardiovascular toxicity assays  
 
It is clear that a drug should be deemed as safe before it is approved. However, 
between 1975 and 2000, of the FDA-approved drugs that were issued new 
black box warnings, about 24% (11 of 45 drugs) were due to cardiovascular 
toxicity and 4 out of the 16 FDA-approved drugs withdrawn from the market 
during this period were also due to cardiovascular toxicity [23]. It turns out that 
this issue is a lot more complicated than finding a binary safe/unsafe answer, 
since certain populations that may not be accounted for during pre-clinical and 
clinical trials may be more susceptible to adverse drug reactions (ADR). This 
indicates that it is hard for clinical trials to ensure the safety of all patients until 
it reaches a larger and more diverse population. As more approved drugs were 
found to be responsible for cardiovascular toxicity, researchers began to identify 
common features of these drugs and developed assays to identify them earlier 
in development.  
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1.2.1 The Classic Paradigm: IKr inhibition  QT prolongation  
Torsade de Pointes  Ventricular Fibrillation 
 
Figure 1.2: Example ECG of a patient with prolonged QT interval  
ECG of a patient with QT prolongation (A) that progressed into Torsade de 
Pointes (B). Adapted with permission from Ref [27]. 
 
Torsade de Pointes (TdP) is a polymorphic ventricular tachycardia that 
produces a particular pattern on an electrocardiogram (ECG), where the QRS 
axis is twisting around a baseline, hence the name “twisting of points”. The 
clinical incidence of Torsade de Pointes (TdP) indicates the potential 
development of a drug-induced arrhythmia and leads to a drug’s withdrawal 
from the market [24]–[26].  
 
The phenomenon was first described in 1964 in patients with “quinidine 
syncope” [28]. This was one of the first clinical demonstrations that drugs could 
induce tachycardia and fibrillation in patients, but it wasn’t understood how. 
Dessertenne coined the term “Torsade de Pointes” in 1966 to describe the 
distinct ECG pattern seen in patients with drug-induced tachycardia and 
fibrillation, after discovering that although the patient had atrioventricular block, 
A 
B 
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the ECG pattern was produced from episodes of polymorphic ventricular 
tachycardia (Figure 1.2) [29]. Upon further investigation of these ECGs, it was 
found that QT interval prolongation, dispersion and alternans increased the risk 
of TdP by altering the QT interval. Inhibition of the main repolarizing potassium 
currents, IKr (hERG/KCNH2 gene) and IKs (KVLQT gene), has been shown to be 
one of the main underlying mechanisms behind drug-induced QT prolongation 
by delaying repolarization of the AP, thereby increasing the action potential 
duration (APD) (Figure 1.3) [30]–[34]. A lot of emphasis has been placed 
specifically on the repolarizing current, IKr, because a lot of toxic non-cardiac 
drugs have been shown to affect IKr and the majority of mutations found in 
patients with congenital Long QT Syndrome (LQTS) were present in KVLQT (75 
of 177 mutations) and hERG (80 of 177 mutations) [35], [36]. As a result, IKr 
inhibition and QT interval prolongation receives a lot of weight in making a pre-
clinical assessment on the safety of a drug.  
 
The issuance of new black-box warnings and the withdrawal of FDA-approved 
drugs due to cardiovascular toxicity brings into question the extent at which pre-
clinical studies predict what happens in the clinic. Verapamil is one of several 
drugs that has taught us that hERG/IKr inhibition should not be the sole 
determinant when assessing for drug-induced toxicity. Verapamil is an IKr 
antagonist but has a low arrhythmogenic risk at therapeutic concentrations due 
to its other ionic effects, which offset the deleterious consequences of IKr 
inhibition on the QT interval [37]. Assessing for drug-induced cardiac toxicity 
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becomes even less straightforward since QT prolongation does not always lead 
to TdP, and TdP does not always lead to ventricular fibrillation [27], [28], [38]–
[42]. This suggests that better predictive markers and more comprehensive 
assays need to be developed to assess the potential of a drug to induce 
arrhythmia in patients.  
 
The importance of a predictive cardiovascular toxicity assay is to first and 
foremost protect patients, but false positives prevent the development of 
potentially effective therapeutics. A survey to safety pharmacologists, 
toxicologists and pharmacologists on pro-arrhythmia liability assessment in drug 
development conducted and published by the Safety Pharmacology Society 
(SPS) in 2017 revealed that 60% of survey responders would abandon a 
potentially beneficial drug if it displayed IKr inhibition at clinically relevant 
concentrations [43].  
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Figure 1.3: The relationship between different phases of the action 
potential from a ventricular myocyte and features of an ECG.  
The QT interval length (blue segment) is associated with action potential 
duration (dashed orange lines). Adapted with permission from Ref [44]. 
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1.2.2 The CiPA initative: developing a standardized protocol to 
evaluate pro-arrhythmic risk 
 
Driven by the need for improved predictive cardiovascular toxicity assays and 
the development of iPSC-derived cardiomyocytes, national and international 
regulatory bodies have collaborated to create the Comprehensive in vitro Pro-
Arrhythmia Assay (CiPA) initiative to stimulate research and development of a 
highly sensitive and selective pro-arrhythmia assay protocol to assess the 
toxicity of lead compounds prior to entering Phase I clinical trials [45]. The 
general principle of the CiPA approach consists of two phases: one, to 
determine the effect of drugs on cardiac ion channels and in silico cardiac 
models, and two, to validate the results from phase one in iPSC-CMs.  
 
Traditionally, assessment of pro-arrhythmia risk is evaluated with assays that 
measure the effect of a compound on specific ion channels (particularly IKr) and 
drug-induced modulation of action potential (AP) waveform or propagation using 
non-human in vitro or ex vivo models, or changes in cardiac function of non-
human in vivo models. Table 1.1 shows that SPS responders rely on different 
types of assays to judge the clinical potential of drug-induced cardiovascular 
toxicity, reflecting the lack of standardization across institutions [43]. The survey 
also showed that among the responders, 51% frequently record drug-induced 
effects on cardiac AP directly, 46% of responders frequently use iPSC-CMs, 
23% of responders frequently use in silico studies in assessment of drug safety 
11 
 
and 39% of responders reported that their company never conducted in silico 
studies in the last 5 years [43]. Implementing future CiPA guidelines would 
require a lot of companies to revamp their drug toxicity screening approach. The 
SPS survey also illustrates how incongruous the methods to assess 
cardiovascular toxicity are across different research institutions: which cardiac 
ion channels are evaluated, which features of an EKG are important, which (if 
any) positive controls used, temperature at which the experiment was 
conducted, etc. [43]. The CiPA initiative would establish a clear guideline, 
thereby standardizing practices across institutions and increasing 
reproducibility across labs. Also, by designing a multi-faceted approach, the 
CiPA approach would be sensitive to a greater number of mechanisms behind 
cardiac toxicity.  
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Table 1.1: Responders across institutions rely on different models, assays 
and preparations when assessing drug-induced cardiovascular toxicity.  
Published results from the SPS survey [43]. 
 
 
 
 
Which of the following cardiac/cardiovascular assays has your 
company used in the last 5 years? 
Answer options 
Frequently 
used 
Rarely 
used 
Response 
count 
Cell lines stably expressing ion 
channels for determination of drug 
block potency 
89% 11% 66 
ECG recording using implanted 
telemetry technology 
88% 12% 67 
Jacketed External Telemetry (JET) 62% 38% 63 
Ion channel binding assays 57% 43% 68 
Anesthetized animal models 53% 47% 58 
Cardiac action potential recordings 
(Purkinje fiber, papillary muscle, 
others…) 
51% 49% 61 
Human stem cell-derived or induced 
pluripotent stem cell cardiomyocytes 
(iPSC-CM) 
46% 54% 68 
hERG (IKr) channel trafficking 42% 58% 72 
Isolated tissue bath preparations 41% 59% 63 
Isolated Langendorff heart 38% 62% 63 
Isolated cardiac wedge preparation 18% 82% 51 
Proarrhythmia animal models 12% 88% 49 
Zebrafish assays 4% 96% 47 
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1.3 The promises and potential of iPSC-derived cardiomyocytes  
 
With the emerging iPSC technology, researchers without readily accessible 
human cardiomyocytes are able to derive their own or purchase them. The 
seminal paper describing the generation of iPSCs was published in 2006 [6]. 
John B. Gurdon and Shinya Yamanaka received the Nobel Prize in Physiology 
or Medicine relatively quickly after this publication in 2012, reflecting its 
importance and paradigm shifting influence [46]. In addition, there has been 
considerable development in generating pure cultures of chamber-specific 
cardiomyocytes and other cardiac cell types, allowing for investigation of precise 
questions [47]–[55]. iPSC-CMs have been shown to recapitulate the disease 
phenotype of patients in vitro, demonstrating its relevancy as an in vitro model. 
Table 1.2 lists some patient-specific iPSC-CM disease models created for 
studying disease pathology, target identification, and/or drug screening. The 
following section briefly provides examples in the literature that suggests the 
utility of iPSC-CM models for drug development.  
 
1.3.1 Ion channelopathies 
 
LQTS1, LQTS2, and LQTS3 are characterized by the gene containing the 
mutation that disrupts the function of an ion channel and a prolonged QT 
interval. iPSC-CMs derived from LQTS patients with prolonged QT intervals 
exhibit the expected effect of ion channel dysfunction in vitro, namely prolonged 
14 
 
APD and field potential duration (FPD), and appearance of pro-arrhythmic 
depolarizations that occur prior to action potential termination, called early after 
depolarizations (EADs) [7], [56]–[59]. An isoproterenol challenge also increased 
the appearance of EADs as expected, while clinically-used anti-arrhythmic 
drugs reduced the number of EADs, demonstrating the potential for drug 
screening [7], [56], [57]. The patient-derived iPSC-CMs also demonstrated 
increased sensitivity to cardiotoxic drugs, further implicating their potential in 
testing for drug toxicity in vulnerable populations [58]. Another great application 
for iPSC technology to produce well-characterized genetically-based disease 
models is to induce the known mutation(s) in iPSCs derived from healthy 
patients and then differentiate the iPSCs into cardiomyocytes [60]. This is 
especially useful in cases where patient material is not readily accessible.  
 
1.3.2 Congenital Cardiomyopathy 
 
iPSC-CMs derived from patients with congenital cardiomyopathies also reflect 
the patient’s phenotype. One type of congenital cardiomyopoathy, 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is caused by a 
mutation in plakophilin-2 (PKP2), leading to desmosomal abnormalities, fatty 
infiltration, decreased cardiomyocytes in the right ventricle, and life-threatening 
ventricular arrhythmias. ARVC patient-derived iPSC-CMs show the anticipated 
increased lipid accumulation, structural disarray and decreased connexin 43 
expression [61]–[63]. Caspi et al. (2013) and Ma et al. (2013) demonstrated 
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using these patient-derived iPSC-CMs for drug development by showing that 
inhibition of drug-target candidates can reverse or prevent further progression 
of the disease phenotype [61], [62]. Kim et al. used these in vitro models to 
dissect the molecular mechanisms underlying the pathology [63]. iPSC-CMs are 
useful for studying the effects of a mutated protein on cardiac function and 
screen potential drug candidates.  
 
1.3.3 Multi-system diseases 
 
Patient-derived iPSC-CMs can also reflect the cardiac disease phenotype of 
diseases that affect multiple tissue and organ systems. For example, Fabry 
disease where mutation in the GLA gene causes accumulation of 
globotriaosylceramide, particularly in blood vessel cell lining. This causes 
abnormalities in multiple organ systems, such as skin, kidneys, heart, and 
nervous system. To design effective therapeutics, it can be fruitful to investigate 
the effect of the disease on one organ system in isolation, in order to 
discriminate between if the decline of the organ system is a consequence of 
distal system failures or if the selected organ system is one of the primary 
causes of poor patient prognosis. Because of the severity of these multi-organ 
diseases, such as LEOPARD syndrome, Fabry Disease, and Barth Syndrome, 
patients tend to die from cardiomyopathy [8], [9], [64]–[66]. Again, iPSC-CMs 
derived from these patients show the expected phenotype that is observed in 
patients and can be used for drug screening by studying the molecular 
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consequences of the mutation and identifying novel therapeutic targets [8], [9], 
[64]–[66].  
 
Table 1.2: Examples of iPSC-CM disease models created from patient 
tissue 
Disease Year Reference 
LQTS1 2010 [56] 
LEOPARD Syndrome 2010 [64] 
Pompe Disease 2011 [8] 
LQTS2 2011 
2011 
2012 
[7] 
[57] 
[58] 
Familial Dilated 
Cardiomyopathy 
2012 [67] 
ARVC 2013 
2013 
2013 
[61] 
[63] 
[62] 
LQTS3 2013 [59] 
Timothy Syndrome 2013 [68] 
T2DM 2014 [9] 
Fabry Disease 2014 [65] 
Barth Syndrome 2014 [66] 
LQTS = Long QT Syndrome 
ARVC  = Arrhythmogenic Right Ventricular Cardiomyopathy 
T2DM = Type 2 Diabetes Mellitus 
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1.4 The restrictions and reality of iPSC-derived cardiomyocytes  
 
iPSC technology has shown a lot of promise for drug discovery, cell-based 
therapies, and basic research. However, its actual applicability and use is 
stunted due to incomplete differentiation protocols causing iPSC-CMs to be in 
a fetal-like stage of development. Adult cardiomyocytes are rod-shaped and 
undergo a hypertrophic change after birth where they become 30-40 times their 
neonatal size [69], [70]. iPSC-CMs are smaller than adult cardiomyocytes and 
have a circular, triangular or multi-angled morphology, similar to neonatal 
cardiomyocytes, possibly because they have not undergone the hypertrophic 
change. iPSC-CMs also lack T-tubules and have disorganized sarcomeres, 
causing iPSC-CMs to have a decreased contractile force compared to adult 
cardiomyocytes [71]–[73]. Unlike adult cardiomyocytes, iPSC-CMs rely on 
glycolysis as their primary source of energy and have less mitochondria by 
volume [74]–[76]. iPSC-CMs also express more fetal-associated isoforms of 
certain genes. For example, iPSC-CMs mostly express the fetal troponin I 
(TNNI) isoform, slow skeletal TNNI (ssTnI), and express little adult cardiac TNNI 
(cTnI), whereas in adult cardiomyocytes, ssTnI is replaced by cTnI [77], [78]. 
iPSC-CMs also have abnormal calcium-handling properties, which leads to 
spontaneous electrical events and disrupts other Ca2+-dependent pathways and 
voltage-gated channels [79], [80].  
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It is difficult to fully mimic the conditions of cardiac development in vitro, namely 
extracellular matrix remodeling, hemodynamic load, hormones, and electrical, 
chemical and physical signals from neighboring cells [81]–[85]. The SPS survey 
showed that 75% of responders thought that iPSC-CMs are a valuable addition 
to pro-arrhythmia screening assays but only 21% believe that they are 
representative of adult cardiomyocytes and provide reliable data as a nonclinical 
safety assay [43]. Considerable tissue engineering efforts have been able to 
push maturation of iPSC-CMs, for example via substrate support, constant 
electrical stimulation, cyclical stretch, co-culturing, and 3D culturing, but more 
research and development is needed [86].  
 
1.4.1 Electrical abnormality of iPSC-CMs  
 
As described below, the neonatal-like electrophysiological profile of iPSC-CMs 
is a major barrier for research. On top of that, iPSC-CM AP characteristics 
(APD90, maximum diastolic potential (MDP), triangulation, upstroke velocity, 
etc.) vary from lab to lab, making it difficult to compare across the literature. 
Despite this, iPSC-CMs consistently have decreased IK1 (similar to fetal 
cardiomyocytes) and IKs as measured by voltage clamp. They also have a “funny 
current,  If, that is typically present in only fetal and embryonic cardiomyocytes 
and adult cells from the specialized conduction system of the heart [87]. If, also 
known as the pacemaker current, activates at more hyperpolarized potentials 
and causes the diastolic membrane potential to slowly depolarize, leading to a 
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spontaneous action potential. The lack of IK1, an inward rectifying potassium 
current, depolarizes the membrane potential and increases APD [88]. iPSC-
CMs also have immature calcium-handling properties that lead to spontaneous 
calcium release and spontaneous action potentials [80]. In silico models 
demonstrate that the abnormal presence (particularly Ca2+ currents) and 
absence (notably IK1) of currents have an effect on how other currents activate, 
such as INa, NCX and RyR [79], [80], [89]. The depolarized membrane potential, 
due to the lack of IK1, decreases sodium channel reactivation. Spontaneous 
calcium release from intracellular stores activates the NCX, causing it to 
transport more sodium into the cell, and can induce RyR activation. Because of 
these abnormalities, iPSC-CMs have a slower upstroke velocity, a depolarized 
MDP, a more triangular AP morphology, and exhibit spontaneous activity 
(Figure 1.5A and C). With abnormal current activation and behavior, it is difficult 
to ascertain whether the aberrant effect of a drug resulted from either affecting 
a critical target that disrupts the system’s behavior, or if the aberrant effect was 
a consequence of the abnormal system that is not applicable to patients. Also, 
the heterogeneity of channel expression and maturity in iPSC-CMs affects the 
reproducibility of results to certain clinically arrhythmogenic drugs or ion channel 
agonists/antagonists [90]–[93]. iPSC-CM electrophysiology can consistently 
yield predictable results of drug-induced ICaL inhibition and hERG/IKr inhibition, 
but the presence or inhibition of other currents are not consistently inhibited 
across literature [91], [93]. Because of these limitations, researchers must be 
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wary about extending conclusions drawn from experiments with iPSC-CMs to 
adult behavior. 
1.5 Dynamic clamp is a powerful tool  
 
Dynamic clamp is an electrophysiological technique that utilizes a mathematical 
model to calculate a desired electrical output (or target current) to be delivered 
into a target cell and measures the effect of the target current on the cell. The 
mathematical model can represent a specific current, inhibition of a current, or 
another cell. The user can adjust the parameters of the model in order to test 
different hypotheses, such as the effect of a slower inactivation gate, the effect 
of decrease conductance or amount of coupling to other cell types. Dynamic 
clamp was first introduced in 1979 and was used to electrically simulate coupling 
between two cells that were not in contact by measuring the membrane potential 
of two separate beating cell clusters and injecting a scaled amount of current 
into the other cell to mimic gap junctional resistance [94]. In the 90s, dynamic 
clamp was used to study gap junctional coupling between individual 
cardiomyocytes, and mimic disease states that affected coupling between cells 
[95]–[97]. The uses and configurations of dynamic clamp have expanded with 
the increase in computational power, but the principle of the technique remains 
the same. 
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1.5.1 Theory and uses of dynamic clamp  
 
In order to execute dynamic clamp, the user needs: 
1) Electrical access to a target cell(s) via patch clamp to measure the cell’s 
membrane potential (Vm); 
2) A mathematical model describing the target current (Itarget); and 
3) Software and hardware to coordinate measuring the Vm, calculating Itarget, 
and injecting Itarget, in real time. 
 
To answer a research question, a mathematical model is created to reflect an 
electrical current of interest: an endogenous current, or a modified current, a 
current flowing through gap junctions, etc. At every timestep, the mathematical 
model calculates Itarget based on the measured Vm of a cell and injects Itarget into 
another, or back into the same cell (Figure 1.4). The output Vm of the injected 
target cell is a consequence of adding Itarget.  
 
Dynamic clamp can be performed in several different configurations. One 
configuration allows the user to simulate gap junctional coupling by patching 
two separate target cells or clusters of cells (Figure 1.4A). The Vm of both 
patched cells would be measured, and the mathematical model would calculate 
how much current should be injected into one or both cells to simulate 
unidirectional or bidirectional gap junctional coupling, respectively. The user 
would define the parameters (e.g., max conductance through gap junctions, 
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voltage dependence of gap junctions) of the model and could modulate them in 
the experiment to determine the effect on the cells [97]–[101].  
 
Dynamic clamp could also couple a target cell to a virtual cell or current. Only 
one target cell would be patched and the Vm would be input into a mathematical 
model that represents another current, cell, or 2D sheet of cells (Figure 1.4B). 
The user could determine the effect of the mathematical model on the target 
cell’s electrical output. This could mimic the expression or inhibition of a current 
in the target cell, electrical coupling to a cell that would be difficult to patch, or 
the influence of a defined 2D sheet on the cell’s activity [22], [90], [100], [102]–
[105].  
 
Dynamic clamp can also be used to study channel activity during an AP (Figure 
1.4C). The channel of interest, which could incorporate a mutation, would be 
expressed in a non-electrically active cell. This requires patching the expression 
system and the target cell. The expression system would be voltage clamped to 
the Vm of the target cell and the current from channel of interest would be 
measured. That current would then be injected back into the target cell. This 
allows researchers to study the effect of the expressed channel on AP 
characteristics and the activation pattern of the channel during an AP.  
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Figure 1.4: Various configurations of dynamic clamp 
Panel A demonstrates how dynamic clamp can be used to simulate coupling 
between two separate cells. Panel B shows the dynamic clamp configuration to 
couple a cell to a virtual current. Panel C illustrates how dynamic clamp can 
couple the target cell to a channel expressed in vitro.  
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1.5.2 Using dynamic clamp to mimic IK1 in iPSC-CMs 
 
1.5.2.1 IK1: Inward rectifier potassium current  
IK1 plays a predominant role in stabilizing the membrane potential and in 
repolarization in ventricular and atrial cardiomyocytes. It is encoded by the 
KCNJ gene subfamily and the channel composition includes Kir 2.x. IK1 allows 
inward currents at potentials more negative than the equilibrium potential of K+ 
(EK) and an outward current at potentials more positive to EK. As an inward 
rectifier, at more positive potentials during the plateau phase of the AP, IK1 
channels are inhibited by divalent cations and polyamines, decreasing the 
outward current that can be generated and allowing for the plateau phase of the 
AP. When looking at the current produced at different membrane potentials, the 
decreasing outward current produced at more positive potentials is described 
as the negative slope conductance [106]. 
 
IK1 in atrial cardiomyocytes has different properties from IK1 in ventricular 
cardiomyocytes. IK1 in atrial cardiomyocytes has less of a negative slope 
conductance than ventricular cardiomyocytes and does not rectify completely. 
IK1 is more predominant in ventricular cardiomyocytes than atrial 
cardiomyocytes. The tissue-specific properties of IK1 are reflected in the 
differences between ventricular IK1 mathematical models and atrial IK1 
mathematical models.  
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1.5.2.2 Addition of IK1 in iPSC-CMs changes AP morphology 
 
Dynamic clamp has been used in iPSC-CMs to study the impact of the missing 
currents on AP morphology. IK1 was electrically mimicked in iPSC-CMs, 
resulting in a drastic change in AP morphology (Figure 1.5). These dynamic 
clamp experiments showed that IK1 is important for maintaining the resting 
membrane potential, suppressing spontaneous activity, increasing the upstroke 
velocity, increasing the action potential amplitude (APA) and shortening the 
APD (Figure 1.5) [22], [90], [107]–[110]. Using dynamic clamp to supplement 
the missing IK1 current is important to push AP morphology to be more 
electrically adult-like. Overexpression of KCNJ2 in iPSC-CMs reduced 
spontaneous activity and affected AP characteristics similarly to using dynamic 
clamp to inject IK1 [111]. In addition, these iPSC-CMs yielded a clear response 
to IKr inhibition, which was masked by further depolarization and reduced AP 
formation without KCNJ2 expression [111]. Bett et al. (2013) demonstrated that 
IK1 addition was necessary to observe a measurable effect of Ca2+ agonism on 
AP morphology as in its absence MDP would be too depolarized for AP 
generation [90]. These experiments demonstrate the importance of IK1 
expression in iPSC-CMs for drug development. Dynamic clamp could be used 
to transform the immature iPSC-CM electrical phenotype to resemble that of an 
adult cardiomyocyte, by correcting for the main electrophysiological abnormality 
of iPSC-CMs compared to adult human cardiomyocytes.  
 
26 
 
 
 
Figure 1.5: Electrically simulating IK1 in iPSC-CMs makes its AP 
morphology resemble a more adult cardiomyocyte AP.  
A and C represents APs recorded from a ventricular-like and an atrial-like iPSC-
CM, respectively. B and D shows the resulting stimulated AP with dynamic 
clamp addition of IK1. The table below quantifies the AP characteristics with and 
without dynamic clamp. Adapted with permission from Ref [90]. 
 
 
1.5.3 Limitations of dynamic clamp 
 
Dynamic clamp is a powerful tool but relies on obtaining a whole-cell patch 
clamp. This technique requires high technical expertise and is low throughput, 
making it impractical for large-scale drug screening. In order to obtain a whole-
cell patch, a thin hollow glass pipette containing an electrode is carefully placed 
on the cell membrane and a giga-ohm (GΩ) seal is formed to seal the 
circumference of the pipette tip with the membrane. The pipette is filled with an 
intracellular solution that typically mimics the cytosolic ionic composition. The 
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cell is bathed in an extracellular solution that typically mimics the endogenous 
extracellular ionic environment. For the electrode to gain intracellular access, 
the cell membrane could either be ruptured by applying negative pressure, or 
the membrane could be perforated by antibiotics so that the membrane still is 
intact, but certain ions can move across it and the electrode can gain access. 
One antibiotic that is commonly used in perforated patch is gramicidin. 
Gramicidin allows monovalent cations (e.g., Na+ and K+) through, which better 
preserves the intracellular environment compared to ruptured patch where the 
cytosolic solution is quickly replaced by the pipette solution. With both types of 
patch clamp, the volume of the intracellular pipette solution is vastly larger than 
the cytoplasmic volume, such that the cytosolic concentration of permeable ions 
is determined by the pipette solution. This prevents endogenous local ionic 
fluxes and forces the intracellular concentrations to be static, making effects of 
these endogenous local changes unobservable under whole cell patch clamp. 
Dynamic clamp can only electrically represent a current, but biologically, the ion 
channels have an ion specificity and their activation may change intracellular 
concentrations of these ions [105]. The change in intracellular concentration can 
have other downstream effects that are not considered. For example, dynamic 
clamp can mimic a sarcolemmal calcium current but besides changing the 
membrane potential, the influx of calcium also activates downstream pathways 
that affect gene expression or phosphorylation of other ion channels. The 
intracellular sodium concentration activates other exchangers, such as the 
sodium-calcium exchanger or sodium-hydrogen exchanger. Using whole-cell 
28 
 
patch clamp allows researchers to only measure the instantaneous effect of the 
target current.  
 
There are several platforms available to study electrophysiology, but there is a 
trade-off between information content and the throughput of the assay (Figure 
1.7) [112], [113]. Manual patch clamp currently provides the highest information 
content but is the lowest throughput assay. The development of automated 
patch clamp has made patch clamp higher throughput and overcomes technical 
barriers, but is best used for expression systems [114]–[116]. For use in the 
automated patch system, iPSC-CMs need to be dissociated into suspension in 
order to be placed and adhere onto the platform [109]. However, the dissociation 
process is thought to disrupt the membrane and ion channels on iPSC-CMs. 
Ideally, a drug-screening platform would be high throughput and provide high 
information content. Much effort is currently exerted in developing such assays, 
for example, platforms that use optical tools to allow for simultaneous pacing 
and imaging of voltage and/or calcium [117]–[119], video-based assays that 
analyze contraction, calcium flux, and/or voltage [120]–[122], etc. [113], [120]–
[124]. In addition to those approaches, optogenetics is a potential tool that can 
increase the throughput of assays while retaining high information content 
because it can be controlled by altering light intensity, its function is versatile, 
and is genetically expressed. Because of these properties, this thesis aims to 
build an optically-controlled dynamic clamp platform using optogenetic tools.  
29 
 
 
 
 
 
 
Figure 1.6 Representation of in vitro electrophysiological assays to 
measure the effect of drugs on ion channels arranged relatively by 
information content and throughput 
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CHAPTER TWO 
 
OPTICAL DYNAMIC CLAMP: LIGHT-ACTIVATED DYNAMIC CLAMP 
USING IPSC-DERIVED CARDIOMYOCYTES*
 
2.1 Introduction  
 
2.1.1 Outline 
 
iPSC-derived cardiomyocytes (iPSC-CMs) are a potentially advantageous 
platform for drug screening because they provide a renewable source of human 
cardiomyocytes and can be patient derived. As mentioned in Chapter One, an 
obstacle to their implementation is their immature electrophysiology, which 
reduces relevance to adult arrhythmogenesis. To address this, dynamic clamp 
is used to inject current representing the insufficient potassium current, IK1, 
thereby producing more adult-like electrophysiology. However, dynamic clamp 
requires patch clamp and is therefore low throughput and ill-suited for large-
scale drug screening. In this chapter, we present the optical dynamic clamp 
(ODC) method, which uses optogenetic tools to generate target current in lieu 
of an electrode. Furthermore, in the presence of an IKr blocker, ODC revealed 
expected AP prolongation and reduced spontaneous excitation.  
 
                                                          
* A slightly modified version of this chapter is published as Quach, B., Krogh-Madsen, T., Entcheva, E., 
Christini, D. J., Light-activated dynamic clamp using iPSC-derived cardiomyocytes, Biophysical Journal, 
(2018) 
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2.1.2 Optogenetics  
 
Optogenetics was lauded “Method of the Year” in 2010 by Nature Methods 
because of how it revolutionized neuroscience research by allowing for high 
spatial and temporal control over specific neural circuits. Since then, the 
optogenetic toolbox has been improved and expanded. For example, 
depolarizing and hyperpolarizing opsins have been developed to be activated 
by different wavelengths and generate a larger photocurrent [125]–[127]. 
Optogenetic tools have also been developed to be voltage reporters (i.e., 
ASAP1, QuasAr2) or dual-report calcium and voltage (i.e., CaViar) [128]–[130]. 
Opsins are also being developed to conduct specific ionic species [131], [132]. 
As the toolkit expands, so do the possibilities. Besides using opsins to gain 
control over electrical circuits, there are many efforts to develop optically-
controlled methods to simultaneously manipulate electrical activity and measure 
changes in functional output by combining different opsins. This has a lot of 
value in cardiac research because of the need for new assays for drug toxicity, 
as discussed in Chapter One, and to increase the throughput of existing assays. 
This chapter will focus on the approach developed in this thesis, where the 
overarching goal is to translate the dynamic clamp method into an optically-
controlled version that we name “Optical Dynamic Clamp”.  
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2.1.3 Optical Dynamic Clamp (ODC) 
 
The ODC platform aims to translate the pain-staking low-throughput method of 
dynamic patch clamp to an optically-controlled high throughput version. 
Dynamic clamp provides high-content electrophysiology data, but its use is 
limited because of very low-throughput and specialized technical expertise. The 
advent of automated patch clamp with multichannel capabilities works to 
address some of these barriers to use, but is not without limitation, such as the 
need for compatibility with cardiomyocytes. In an important step in this direction, 
Goversen et al. (2018) recently demonstrated using a Nanion Patchliner 
automated patch clamp device to inject IK1 via dynamic clamp into iPSC-CMs 
[102]. Here, we present a light-controlled approach to this problem. The ODC 
platform would also allow for many more trials due to its non-contact nature and 
scalability. In addition, ODC potentially offers more versatility and flexibility over 
electrode-based methods. These advantages are further elaborated upon in the 
discussion section of this chapter. 
 
To realize a fully-optically-controlled dynamic clamp, we must first establish the 
use of optogenetic tools to dynamically inject a target current to observe its 
effect on AP morphology. First, there would need to be an approach to measure 
the membrane potential. Second, there would need to be a way to inject a 
dynamic current. The aim of the thesis is to address the second function first. 
There are different optical methods present to measure membrane potential, 
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but there are no published contact-less methods to introduce a specified current 
into a cell.  
 
Optogenetic tools are a potential solution because they can generate a 
depolarizing current and a hyperpolarizing current into a cell expressing that 
opsin. They are typically used to generate a static current to stimulate action 
potentials or completely inhibit electrical activity. An optical action potential 
clamp has been used to uncover the dynamic contribution of Channelrhodopsin-
2 (ChR2), a depolarizing opsin, during the cardiac action potential [133], [134]. 
Several computational [133], [135] and experimental studies [136], [137] have 
used depolarizing and hyperpolarizing opsin to modulate the cardiac AP 
morphology.  For example, activation of ChR2 by static light pulses delivered 
during different AP phases extended the action potential duration (APD) in 
neonatal rat ventricular myocytes (NRVM) [137]. Hyperpolarizing anion 
Channelrhodopsin 1 from Guillardia theta (GtACR1) was optically activated by 
static pulses to shorten the APD in NRVMs via forced hyperpolarization [136]. 
Static optogenetic manipulation can yield a range of AP responses depending 
on pulse timing, strength and duration [133]; however, it has inherent limitations 
when applied to multicellular tissue, where cells are at different phases of the 
AP at any given time. Computationally, a ChR2 model [134] was used to add a 
dynamic depolarizing current to simulate short QT syndrome and resemble a 
target AP, yet no real-time feedback was used [135]. Although this method 
worked well in silico, it would be critical to incorporate a real-time feedback loop 
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to address inherent cell variability and make the approach AP-morphology-
adaptive.  
 
In this study, to demonstrate the use of optogenetics to dynamically tune an AP, 
we used Archaerhodopsin TP009 (ArchT) [125], [126] to optically generate 
target outward current IK1, instead of using electronic current injection via a 
patch electrode. ArchT has proven to be a useful tool to inhibit electrical activity 
in different excitable cells [125], [138]–[142]. To actualize the real-time feedback 
loop, the optogenetic tool must have fast kinetics and generate sufficient 
current.  For validation purposes, we compared the use of the ODC platform 
with the standard electrode-based dynamic clamp (EDC) platform to generate 
a target current mimicking IK1 in human iPSC-CMs. We also investigated 
whether ODC would be able to uncover, as EDC would, the effects of the hERG 
channel inhibitor, E-4031, to illustrate ODC applicability to detect the effect of 
pharmacological agents on electrical activity. Our experiments demonstrate that 
ArchT can be controlled to generate the target current and yielded results similar 
to that of using an electrode, even in the presence of an ion channel modulator, 
corroborating the utility of optogenetic tools in the dynamic clamp setting and in 
drug testing applications.  
 
In this implementation, we use the outward-current-generating opsin, ArchT, to 
mimic IK1, resulting in more adult-like action potential (AP) morphology, similar 
to IK1 injection via classic dynamic clamp. The ODC presented here still requires 
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an electrode to measure Vm, but provides a first step towards contactless 
dynamic clamp, which will not only enable high-throughput screening, but may 
allow control within multicellular iPSC-CM formats to better recapitulate adult in 
vivo physiology. 
 
2.2 Methods 
 
2.2.1 Cell Culture 
 
Cor.4U hiPSC-CMs (Axiogenesis, Cologne, Germany) were thawed, seeded, 
and maintained according to the protocols provided by the manufacturer. The 
cells were seeded on 0.1% gelatin-coated 8mm coverslips and plated at 
100,000 cells/mL. Cells were incubated for at least 7 days post thaw prior to use 
for experiments. 
 
2.2.2 Infection and Expression of ArchT 
 
Adenoviral vector was constructed using the Addgene (Cambridge, MA) 
plasmid pAAV-CAG-ArchT-GFP, deposited by K. Deisseroth’s laboratory 
(plasmid 20940) [143], [144]. ArchT was expressed in iPSC-CMs using MOIs of 
250-300, as described in previously published protocols using an adenovirus 
[143], [144]. Determination of successful infection was confirmed via eGFP 
fluorescence. Functionality of ArchT was confirmed by illuminating the cells with 
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an LED (M565L3, ThorLabs) at 595 nm through a 60x objective and observing 
the amount of hyperpolarization of the membrane potential under current clamp.  
 
2.2.3 Electrophysiology Protocol 
 
Borosilicate glass pipettes were pulled to a resistance of 1-3 MΩ using a 
flaming/brown micropipette puller (Model P-1000, Sutter Instrument). The 
pipettes were filled with intracellular solution containing (mM) 10 NaCl, 130 KCl, 
1 MgCl2, 10 CaCl2, 5.5 Dextrose, 10 HEPES. For perforated patch, the pipette 
tip was first dipped into the intracellular solution without gramicidin for 10 
seconds. The pipette was then filled with the intracellular solution containing 8 
µg/mL gramicidin passed through a 0.25 µm filter. The high calcium 
concentration in the intracellular pipette solution serves to verify the integrity of 
the patch as patch rupture under these conditions would lead to immediate cell 
contracture [88]. The coverslips containing iPSC-CMs were placed in the bath 
and constantly perfused with an extracellular solution at 37°C containing (mM) 
137 NaCl, 5.4 KCl, 1 MgSO4, 2 CaCl2, 10 Dextrose, 10 HEPES. GFP-
expressing single cells that were visibly contracting were chosen for 
experiments. Patch-clamp measurements were made by a patch-clamp 
amplifier (Model 2400, A-M Systems, Inc) controlled by the Real Time 
eXperiment Interface (RTXI; www.rtxi.org) to coordinate the amplifier via the 
data acquisition card (PCI-6025E, National Instruments). RTXI was also used 
to control the LED light intensity. The voltage was corrected for the calculated  
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liquid junction potential of -2.8 mV. The series resistance was less than 10 MΩ 
and was not compensated. 
 
2.2.4 Dynamic Clamp Experiments 
 
Figure 2.1A depicts the schematic of the EDC system. At each time step, the 
electrode measures the membrane potential (Vm), which is then input into a 
mathematical model of IK1 to determine the amount of target current that should 
be generated at that measured Vm. The amplifier outputs the calculated target 
current in real-time, simulating the expression of an equivalent current within 
the cell.  
 
Figure 2.1B illustrates the ODC system. Similar to the EDC system, the 
membrane potential measured by an electrode is input into the mathematical 
model of the target current. We used the IK1 equations of the human ventricular 
myocyte model by ten Tusscher et al. (2004). The maximum allowable Itarget was 
set to 1.08 pA/pF because that was close to the maximum current that could be 
generated by ArchT in these cells. ArchT is a proton pump, generating a light- 
and voltage-sensitive outward current. There is no published validated 
mathematical model for the ArchT ion current. Instead, we used an empirical  
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Figure 2.1: Description of EDC and ODC systems 
Dynamic clamp is used to simulate the target current, IK1, in iPSC-CMs. (A) The 
EDC system uses the electrode to measure the Vm and inject a current into the 
cell. (B) The ODC system utilizes the electrode to measure the Vm, but uses 
optical ArchT activation to inject the target current. Prior to implementing the 
ODC system, a calibration protocol is executed to obtain the parameters to 
generate a cell-specific ArchT model.  
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equation that was tuned on a per-cell basis to generate the illumination Ee 
needed to achieve the target current, IArchT: 
where the first component describes the voltage dependence, which is linearly 
affected by the membrane potential, and the second component describes the 
light intensity dependence of ArchT (Equation 2.1, Figure 2.2). Due to an 
amplifier calibration error, the Vm used in this calculation by RTXI (Vm*) was later 
determined to be of 5% smaller amplitude than the real Vm as recorded by the 
amplifier. This error affects IArchT equally in the EDC and ODC systems and 
simulating its effects in a mathematical iPSC-CM model (Paci et al., 2013) 
suggests that it has no significant impact on dynamic clamp performance 
(Appendix A10). The parameter Vrest is set to -85 mV, the ideal resting 
membrane potential. Ee represents the light intensity of the LED. a1 and a2 
describe the cell-specific voltage dependence while b1 and b2 describe the cell-
specific light intensity dependence. The values of these parameters are 
determined for each cell with a calibration protocol prior to running the ODC 
platform so that the ArchT model represents the characteristics from an 
individual cell. In about half the cells, inward current events are generated 
spontaneously even during voltage clamp at -85mV (Appendix A2). These 
spontaneous events may obscure the recorded current and thus the 
determination of the cell-specific ArchT parameters. However, cells in which 
these disturbances did occur were not associated with a reduction in ODC 
  IArchT =  a1 ∙ Vm*+a2 
a1 ∙ Vrest+a2  ∙  b1 �1 −   e−b2 ∙Ee�,  (Eq. 2.1) 
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performance, measured as pre-stimulation potential, fraction of repolarization, 
and triangulation.  
 
To test the feasibility of using ArchT to inject a target current, stimulated action 
potentials under the EDC system were compared to those of the ODC platform 
at three different pacing frequencies: 0.5, 1 and 2 Hz. The cells were stimulated 
10 times at 0.5, 1 and 2 Hz sequentially under three conditions (the order of 
which was randomized): (A) control, in which no additional current was added, 
(B) addition of Itarget with EDC, and (C) and addition of Itarget with ODC.  
 
2.2.5 E4031 addition 
 
After the cells had undergone the aforementioned pacing protocol under the 
same three conditions, 500 nM E-4031 was perfused into the bath containing 
the coverslip of iPSC-CMs for 2 minutes.  Experiments were again conducted 
under the same pacing protocol and conditions to measure the effect of IKr 
inhibition.  
 
2.2.6 Analysis  
 
APDX was calculated by determining the time from stimulus to the time point at 
which the AP repolarized X% of the AP amplitude (AP peak – pre-stimulation 
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potential). The AP peak was defined as the maximum membrane potential 
reached during the AP after delivered stimulus. The pre-stimulus potential is 
defined as an average of the membrane potential in the last 50 ms prior to 
delivering a stimulus current. The fraction of repolarization, calculated as 
(APD90-APD50)/APD90, and triangulation, calculated as APD90-APD30, were 
used as metrics to quantify AP morphology. Data measured at a given pacing 
frequency in a cell were omitted from the analysis of AP characteristics if they 
contained more than one spontaneous event under EDC or ODC. This 
exclusion was necessary because spontaneous activity could affect the 
subsequent stimulated AP, obscuring the comparison between EDC and ODC. 
 
2.3 Results 
 
2.3.1 Cell-Specific Calibration 
Intrinsic cell-to-cell variability of ArchT expression and characteristics 
necessitated a calibration protocol that determines the cell specific parameters 
of the IArchT model (Eq. 2.1). The calibration protocol consists of a voltage-clamp 
protocol and a light-clamp protocol (Figure 2.2A). The light intensity ramp of the 
protocol highlighted in blue is used to determine the parameters describing light 
dependence of IArchT, while the voltage steps highlighted in purple are used to 
obtain the parameters quantifying its voltage dependence. Figure 2.2B depicts 
the example current trace during the light intensity ramp on an extended time 
42 
 
axis and Figure 2.2C shows the current during each of the three voltage clamp 
steps. These data are used to obtain the cell-specific parameters by determining 
the best-fit line using a nonlinear least squares analysis. By deriving the cell-
specific ArchT parameters, the light intensity can be accurately calculated to 
activate ArchT and generate the target current in individual cells. 
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2.3.2 ODC achieves results similar to EDC 
 
After obtaining the cell-specific parameters for Eq. 2.1, we then used the ODC 
method and evaluated its performance compared to EDC. Results from one 
representative cell paced at 0.5, 1 and 2 Hz are illustrated in Figure 2.3. The 
control yielded a lot of spontaneous activity, making it difficult to trigger a 
stimulated AP or skewing the subsequent stimulated AP. The EDC and ODC 
platforms hyperpolarize the membrane potential and inhibit the occurrence of 
spontaneous events. The stimulated APs in the EDC and ODC conditions are 
very similar, demonstrating that the EDC and ODC platforms yield nearly 
identical stimulated APs at different pacing frequencies despite their 
fundamentally different methods of injecting a current. The EDC target current 
also overlaps with the ODC target current, as would be expected to generate 
similar APs.  Similar to IK1, the target current is on between APs to maintain the 
resting membrane potential. During the early phases of the action potential, the 
target current turns off and then increases during repolarization as IK1 would 
behave. These results indicate that the ODC platform is able to calculate a 
target current, determine the light intensity needed to generate that target 
current, adjust the LED output, activate the optical tool, and successfully 
generate the target current. In short, it demonstrates the feasibility of ArchT to 
inject a target current analogous to injection via an electrode. 
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Figure 2.3: Example demonstrating the results of the EDC and ODC 
platforms  
Two stimulated APs from an example cell (cell 1, Appendix A6A and A8) 
showing the effects of adding Itarget (IK1) while paced at three different 
frequencies: (A) 0.5 Hz, (B) 1 Hz, (C) 2Hz. The top panels in each of (A) through 
(C) overlay the paced APs over time under control and both dynamic-clamp 
conditions, and the black triangles indicate when a stimulus current was 
delivered. In the middle panels, the traces represent the calculated target 
currents for EDC and ODC. The bottom panels show the calculated light 
intensity used to generate the target current. The time axis corresponds to the 
time within the full recording shown in Appendix A6A.  
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Figure 2.4: Example demonstrating the results of the EDC and ODC 
platforms  
Figure is organized in the same manner as Figure 2.3. This example is from cell 
13 (Appendix A6B and A8). The time axis corresponds to the time within the full 
recording shown in Appendix A6B.  
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While the cell presented in Figure 2.3 is representative of the most common 
ODC performance (11 of 16 cells with similar results), in a subset of cells (5 of 
16), ODC was unable to maintain the resting membrane potential as well as 
EDC so that there is a greater than 5 mV difference in the pre-stimulation 
potential between EDC and ODC. Figure 2.4 shows a cell that illustrates this 
behavior. The gradual depolarizing drift of the ODC membrane potential led to 
an increase in the target current (and therefore light intensity) as the ODC 
attempted to hyperpolarize the membrane potential. Although the light intensity 
did increase, the membrane potential could not be maintained, potentially 
because ArchT did not generate the required target current. Despite the 
difference in the pre-stimulation potential, both dynamic clamp systems had a 
similar effect on the overall morphology of the stimulated APs, which can be 
seen by the degree of overlap of the EDC and ODC AP traces. EDC and ODC 
both inhibited spontaneous activity similarly to the cell in Figure 2.3, allowing for 
better measurement of the AP waveform whereas without outpacing the intrinsic 
spontaneous rate, it was difficult under the control condition to measure an AP 
without a preceding spontaneous event.  
 
Figure 2.5 summarizes the effect of EDC and ODC across 16 individual cells on 
the pre-stimulation potential (Figure 2.5A), triangulation (Figure 2.5B) and the 
fraction of repolarization (Figure 2.5C). EDC and ODC have the advantage over 
the control condition of suppressing the rate of spontaneous activity, especially 
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when the pacing rate is less than the intrinsic rate (Appendix A3). Both dynamic 
clamp systems hyperpolarize the pre-stimulation potential compared to the 
control (Figure 2.5A). Ideally, we would expect ODC to hyperpolarize the pre-
stimulation potential to the same value as EDC. In 11 of 16 cells (e.g., cell in 
Figure 2.3), the pre-stimulation potential in both ODC and EDC were within 5 
mV of each other. However, as mentioned above, in 5 of 16 cases, (e.g., cell in 
Figure 2.4), the pre-stimulation potential of the ODC was depolarized more than 
5 mV relative to EDC because ODC did not maintain the membrane potential 
as well as EDC did. This is reflected when comparing the average pre-
stimulation potentials across conditions (Figure 2.5D). Despite the more 
depolarized pre-stimulation potential, ODC had similar effects as EDC on the 
overall AP morphology. As one marker of AP morphology, we used fraction of 
repolarization, which quantifies the fraction of the AP that is spent in the 
repolarization phase. We expect the fraction of repolarization to decrease with 
dynamic clamp, given that IK1 contributes to late repolarization. The ODC 
affected the fraction of repolarization by the same magnitude as EDC on 
average (Figure 2.5D) and this is also seen on an individual basis (Figure 2.5C). 
Triangulation provides another marker of the overall shape of the AP. In most 
cells, ODC altered triangulation by similar magnitudes as EDC (Figure 2.5E). 
The overall average across all pacing frequencies also demonstrates that ODC 
had a similar effect on triangulation as EDC (Figure 2.5F). Further AP 
characteristics are provided in Appendix A.13. In summary, comparing the AP 
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characteristics under EDC and ODC reaffirms that ArchT is able to recapitulate 
similar effects as an electrode on AP morphology.  
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2.3.3 ODC platform detects effect of IKr inhibition similar to EDC 
 
To investigate the feasibility of using the ODC platform for drug screening, it is 
important to determine if ODC can detect changes in AP morphology similar to 
EDC in the presence of an ion-channel modulator. We used an IKr inhibitor, E-
4031, because IKr is a dominant repolarizing current in iPSC-CMs and IKr 
inhibition assays are commonly used as drug toxicity assays. Figure 2.6 shows 
an example after E-4031 treatment, demonstrating that the ODC platform 
mimics the effects of EDC on AP morphology. With E-4031 addition, the APD 
increases in the control, EDC and ODC conditions, as expected with IKr inhibition 
(Figure 2.6A-C). Importantly, it is easier to observe the E-4031 induced AP 
prolongation under EDC and ODC compared to the control because there is 
less spontaneous activity (Figure 2.6A-C). That said, like in Figure 2.4, ODC 
does not maintain the membrane potential as well as EDC between APs, which 
can be seen in the different pre-stimulation potentials (and non-overlapping 
target currents) (Figure 2.6D). However, the overlapping EDC and ODC 
stimulated APs and target currents during the AP indicate that ArchT achieved 
a similar effect as the electrode on AP morphology even if the same pre-
stimulation potential was not achieved (Figure 2.6D, E). Thus, the ODC platform 
behaves like EDC in illuminating the expected changes on AP morphology and 
APD prolongation with E-4031 addition.   
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Figure 2.6: Example demonstrating the results of control, EDC and ODC 
after E-4031 addition 
Example cell (cell 13, Figure 2.7) showing the effects of adding Itarget while 
paced at 0.5 Hz. The gray (A, D), orange (B, D, E) and green (C-E) traces 
represent the control without any current addition, adding Itarget with EDC and 
adding Itarget with ODC, respectively. (A-C) The darker traces represent the 
stimulated APs after E-4031 addition, while the light-colored traces represent 
the stimulated APs prior to E-4031 addition. (D) Overlays of AP traces from the 
three conditions after E-4031 addition. (E) Calculated target currents for EDC 
and ODC. Black triangles indicate when a stimulus current was delivered and 
provides a reference to which of the 10 paced APs in Appendix A9 are 
displayed. The time axis corresponds to the time within the full recording shown 
in Appendix A9. 
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The effect of E-4031 with EDC and ODC across all cells is depicted in Figure 
2.7. In all cells, EDC and ODC were able to inhibit spontaneous activity seen in 
the absence of dynamic-clamp, allowing for an accurate measurement of AP 
characteristics. E-4031 increased the APD90 under control, EDC and ODC 
conditions, as expected (Figure 2.7A). Addition of simulated IK1 via both dynamic 
clamp platforms shortened the APD90 compared to the control, as expected 
with increased repolarizing current. ODC also shortened the APD90 to the same 
magnitude as EDC in individual cells and on average across all cells (Figure 
2.7A, E). Cell 13 under the control condition yielded too much spontaneous 
activity after drug addition so that pacing did not override the intrinsic activity to 
yield stimulated action potentials. Similar to previous results without E-4031, the 
effect of ODC and EDC on pre-stimulation potential, fraction of repolarization 
time and triangulation compared to the control are similar (Figure 2.7B-D). The 
average of characteristics across all cells confirm the overall AP morphology 
(APD90, fraction of repolarization, and triangulation) is nearly identical between 
EDC and ODC (Figure 2.7H). Of note, with E-4031, the control (without dynamic 
clamp) cells exhibited more dramatic drug-induced effects in terms of APD 
prolongation and larger triangulation compared to EDC and ODC, which likely 
indicates that in lack of sufficient IK1, the hiPSC-CMs may be overly sensitive to 
classic hERG channel blockers. The agreement between the optical dynamic 
clamp and electrode dynamic clamp in the presence of E-4031 illustrates how 
ArchT can be used in place of an electrode in the context of drug screening. 
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Figure 2.7: Summary of the effect of adding IK1 via EDC or ODC after E-
4031 addition on AP morphology paced at 0.5 Hz 
The APD90 (A), pre-stimulation potential (C), fraction of repolarization (E) and 
triangulation (G) were measured without any current addition (grey), and with 
the addition of Itarget via EDC (orange) or ODC (green) in individual cells (A) The 
empty markers represent the APD90 prior to drug addition and the dark circles 
represent the APD90 after E-4031 addition. Average of all cells and standard 
error mean (SEM) of the APD90 after drug addition (B), pre-stimulation potential 
(D), fraction of repolarization (F) and triangulation (H) by pacing frequency; 
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2.4 Discussion  
 
2.4.1 Optical Dynamic Clamp performance and limitations 
 
Dynamic clamp is a technique that enables versatile and thorough probing of 
electrophysiology. However, its use for drug screening is limited because its 
standard implementation is low throughput. An optically-controlled version 
would enable more high throughput applications. Here, we have conducted 
proof-of-concept experiments, in which ArchT was controlled optically, injecting 
the IK1 target current and altering AP morphology similarly to electrode-based 
dynamic clamp. Our findings demonstrate: 1) the feasibility of using 
optogenetics to generate a dynamically controlled target current and 2) the ODC 
platform has the potential to be used for drug screening in place of EDC.  
 
One shortcoming of ODC with respect to EDC was the decreased ability of ODC 
to maintain a hyperpolarized membrane potential between APs in some cells. 
The resulting differences in pre-stimulation potential could conceivably cause 
secondary changes in AP features. However, this possibility was ruled out, as 
there was no correlation between the difference in pre-stimulation potential 
between EDC and ODC on the differences of fraction of repolarization and 
triangulation (Appendix A4). One explanation for the inability of ArchT to 
maintain a hyperpolarized membrane potential as well as EDC does is the 
relatively low maximum current that a light-driven ion pump can generate. 
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Indeed, ArchT pushes one H+ ion per photon, which is much less efficient than 
the operation of a light-sensitive ion channel. Furthermore, the ArchT current 
seemed to decay during the voltage-dependence part of the calibration protocol 
(Figure 2.2C). During the intervals between APs, such ArchT current decay 
could depolarize the membrane. We tested this hypothesis by quantifying the 
correlation between the cell-specific current decay and the difference between 
the pre-stimulation potentials between EDC and ODC (Appendix A5). No such 
correlation was found, suggesting that it is unlikely that the current decay is 
responsible for the lack of Vm maintenance.  
 
Another potential limitation of ODC is that because ArchT is a proton pump, 
there may be a pH effect. Archaerhodopsins themselves are known to be pH 
sensitive, so a local change in pH could affect the ability of ArchT to generate a 
consistent current [145]–[147]. Local changes in pH could affect neighboring ion 
channels directly or indirectly by affecting the membrane and altering the overall 
electrophysiological properties of the cell [147]–[150]. The observation that 
ODC inhibited spontaneous activity more effectively than EDC (Appendix A3) 
may be evidence of this effect on other ion channels either by directly affecting 
the structure of the proximal channels or indirectly by altering the surrounding 
membrane properties. The increased inhibition of spontaneous activity with 
ODC can serve as an advantage over EDC since AP morphology can be 
measured without any distortion from underlying spontaneous events.  
 
58 
 
In some cells, we observed a voltage undershoot following the AP (Figure 2.4, 
Appendix A4) [7], [87], [151]–[153], [56], [67], [154], [155], [62], [156], [157]. The 
magnitude of this undershoot varied across cells. EDC was better able to inhibit 
this undershoot by injecting a depolarizing current (Appendix A4); not 
surprisingly, the hyperpolarizing opsin was not helpful in correcting this feature. 
The cause and consequences of this undershoot are not fully understood but 
can account for the differences between the ODC and EDC and explain why in 
some cases, the AP morphology with ODC looks more like the control than EDC 
(Appendix A7). The increased hyperpolarization seen in control and ODC 
conditions may have consequences for the subsequent AP by altering the 
activation state of other ion channels. Extension of the ODC method to 
incorporate a depolarizing opsin would allow bi-directional voltage control, and 
thereby compensate for the undershoot, similar to EDC. Indeed, this would 
allow the optical dynamic clamp to mimic any electrical current and thereby be 
fully versatile like EDC. Finally, there are limitations to our empirical approach 
to modeling ArchT as an on/off light switch in Eq. 2.1. Taking into account the 
ArchT’s intermediate states of different conductance [126], [158], and 
developing more mechanistic models, as done for ChR2 [134], may help 
improve similarity between EDC and ODC.  This will allow for better control of 
light levels and more precise generation of the predicted current.  
 
The maximal Itarget of 1.08 pA/pF used in our study was determined based on 
the maximal current that could be consistently generated by ArchT in the voltage 
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range relevant to IK1. The Itarget generated during our dynamic clamp 
experiments typically did reach 1.08 pA/pF during final repolarization (e.g., 
Figure 2.3), and did reach maximum during rest (where the maximum is around 
0.5 pA/pF due to decreased driving force).  We expect that a larger Itarget would 
allow hyperpolarization to below the -80 mV level as seen in previous studies of 
EDC [21], [109], [154].  
 
Dynamic clamp is based on a real-time feedback look and because ArchT is not 
an instantaneous current, there is the potential that its kinetics are slow for the 
purposes of dynamic clamp. We investigated the effect of the time constant of 
activation and deactivation on dynamic clamp performance in silico (Appendix 
A11A). The in silico results suggest that there is tolerability of the ODC system 
to accommodate a time constant of less than 60 ms, before the resulting AP 
waveform deviates substantially from the control. We measured the time 
constant in our cells to be less than 15 ms and therefore within the range of 
tolerability as predicted by our in silico experiment (Appendix A11A).  
 
We have yet to eliminate the need for an electrode by incorporating an optical 
method to measure the membrane potential. When making this platform fully 
optical, there are several anticipated challenges worth discussing. Currently 
available optical methods of measuring membrane potential are voltage-
sensitive dyes and other opsins (e.g., QuasAr2, Arch(D95X), and CaViar) [159], 
[160]. These options do not measure the absolute membrane potential, which 
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is required in the present setup to calculate the target current. Hou et al. (2014) 
reported a method of using the temporal dynamics of microbial rhodopsin 
fluorescence to measure the absolute membrane potential, but it is not 
compatible with the mechanics of dynamic clamp [161]. The noise of fluorescent 
markers may cause the calculated Itarget to fluctuate, possibly affecting the 
accuracy of the dynamic clamp. In addition, dynamic clamp relies on the real-
time feedback of information, so a fully-optical dynamic clamp platform would 
require a stable and rapidly responsive voltage sensor. Realization of the fully-
optical dynamic clamp dream will require development of optical tools that are 
conducive to dynamic clamp.  
 
2.4.2 Using optical dynamic clamp for drug screening 
 
The tedious nature of dynamic clamp restricts its use, but were it high 
throughput, it would open the possibility for its use during pre-clinical drug 
development. To increase throughput, an all-optical system would require an 
optical voltage readout, using, e.g., a voltage sensitive dye (VSD) or a 
genetically encoded voltage indicator (GEVI). The necessary requirements for 
compatibility in the ODC system would be defined by phototoxicity, brightness, 
responsiveness, and wavelength crosstalk.  One of the biggest advantages of 
the ODC platform is that it is compatible with a variety of cell formats. In 
spatially-extended systems (e.g., large beating clusters and monolayers), the 
EDC platform is not applicable, while the ODC platform can be used to illuminate 
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the arrhythmogenic effects of drugs. There are also many engineering methods 
and platforms that aim to physically mimic in vivo developmental conditions (i.e., 
extracellular matrix composition and organization, and cyclical stretch) [162]–
[165]. These more tissue-like formats capture “in-context” cell behavior, 
including electrotonic coupling and other chemical influences from neighboring 
cells, and therefore are preferred to single cells.  Furthermore, all-optical 
methods enable high-precision space-time control in such multicellular systems, 
as illustrated recently in neurons [166] and in cardiac preparations [167]. This 
allows users to re-direct the control of electrical activity from the single-cell 
behavior to the emergent (wave) behavior  [167], [168]. 
 
2.4.3 Versatility and flexibility of ODC 
 
With the right optogenetic tools and mathematical models, the optical dynamic 
clamp platform could open up more physiologically relevant formats for basic 
science research and drug development. Halorhodopsins, such as 
Natronomonas pharaonis halorhodopsin (NpHR) and its derivatives could also 
be used in this platform as an alternative to ArchT to inject a hyperpolarizing 
current given its fast kinetics [169]. Neither of these generate particularly high 
current, considering that they are light-sensitive ion pumps. GtACR1 is a Cl- 
current with large amplitude [136], [170] that is also fast and thus very promising; 
its utility in adult cardiomyocytes and physiological concentrations remains to 
be demonstrated. BLINK1 is the first potassium-selective optogenetic tool 
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available, but its kinetics are currently too slow for the near real-time feedback 
requirements of ODC [131]. There are also several depolarizing opsins 
available that can be used in conjunction with hyperpolarizing opsins, so that 
any inward or outward current can be represented in cardiomyocytes[169], 
[171], [172]. Optogenetic tools are being engineered to activate/deactivate 
faster, generate larger photocurrents, be permeable to specific ionic species or 
be activated by specific wavelengths. As these developments progress, users 
can choose which optogenetic tool best suits their needs in the ODC platform.  
 
One known drawback of EDC is that an electrode can only electrically mimic a 
current but cannot account for endogenous secondary effects that affect 
electrophysiology, such as activation of exchangers, pumps, or Ca2+-dependent 
processes, which typically result from the change in intracellular ionic 
concentration. In this regard, because optogenetic tools alter the membrane 
potential by changing the intracellular ionic composition, the ODC platform may 
be more suitable for dynamic clamp than using an electrode because 
optogenetics can generate a custom-tailored current with the intended ionic 
species itself, reflecting how endogenous currents are generated. As with the 
standard dynamic clamp method, ArchT mimicked the electrical behavior of IK1. 
But as potassium-selective tools are made compatible with the dynamic clamp 
system, the ODC platform may recapitulate both the electrical effect of IK1 and 
its effects from altering the intracellular potassium concentration. With the 
expansion of the optogenetic toolbox, the ODC platform will more accurately 
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investigate true influence of an ionic current on electrophysiological behavior by 
generating the current with the relevant species.  
 
Optogenetic tools are being creatively incorporated into automated high-
throughput drug screening platforms [117], [159], [173]. Using optogenetic tools 
dynamically could also potentially expand on the use of automated multi-
channel patch clamp systems to multicellular preparations. Such a hybrid 
system could continue to use a patch electrode to read the Vm but instead use 
optogenetic methods to inject a dynamic current into the multicellular format. 
The ODC method contributes a novel approach to probe electrical dynamics in 
iPSC-CMs and to better reveal how electrical activity is controlled. Here, a proof-
of-principle ODC application was demonstrated with ArchT to generate IK1 as 
target current in iPSC-CMs to simulate a more adult-like electrical phenotype. 
As the ODC platform develops, it should be possible to simulate abnormal 
currents or simulate heterogeneous current expression in iPSC-CM 
monolayers. This would provide a more powerful approach that enables 
researchers to address hypotheses that could not be investigated previously. 
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CHAPTER THREE 
 
USING THE OPTICAL DYNAMIC CLAMP FOR SCREENING ION CHANNEL 
MODULATORS 
 
3.1 Introduction  
 
3.1.1 Outline 
 
Chapter 2 presented the proof-of-concept of using optogenetics in lieu of an 
electrode to inject a target current, with the application of creating an optically-
controlled version of dynamic clamp. In this chapter, the ODC platform is applied 
to drug screening of ion channel modulators. This chapter aims to investigate to 
what extent ODC can replace EDC and respond similarly to ion channel 
modulators. By determining this in single cells, we will be able to determine the 
effectiveness of this method compared to the status quo before extending the 
platform to further applications and expanding the platform to a greater variety 
of formats. Chapter 3 also aims to demonstrate the possible benefit of adding 
IK1 for drug screening. Using electrode-based dynamic clamp, Bett et al. (2013) 
demonstrated that the anticipated AP prolonging effect of the calcium channel 
agonist bayK 8664 was only observable when injecting an IK1-like current [154]. 
In addition to the potential ease of use of the ODC platform, the extension to 
physiologically relevant formats that better resemble tissue-level properties may 
make the ODC platform more selective and sensitive than other 
electrophysiology-based platforms for predicting toxic or beneficial effect of 
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drugs in patients. As the results in this chapter will show, while our experiments 
demonstrate that the ODC platform can detect the anticipated effects of the ion 
channel modulators on AP characteristics, it also reveals some limitations in 
how effectively the current implementation of ODC can mimic EDC for drug 
screening. In addition, we were unable to demonstrate the benefit of using 
dynamic clamp to add IK1 with BayK 8664.  
 
In this chapter, the following drugs were selected: BayK 8664, verapamil, and 
terfenadine. iPSC-CMs, without dynamic clamp, reflect the effect of verapamil 
and terfenadine through changes in AP characteristics that are driven by the 
activation of the ion channels that the drugs target. Because iPSC-CMs are able 
to respond predictably to these well-characterized ion channel modulators [174], 
[175], the condition without dynamic clamp serves as a good control in our 
experiments to ensure that the drug is active and the cells are responding 
appropriately to the drug based on the effect on AP characteristics. The EDC 
platform will demonstrate the effect of our target current on the results of the 
drug screen and will be used as a comparison of how ODC should ideally 
perform. iPSC-CMs with addition of IK1 via EDC has been demonstrated to be 
able to detect the anticipated AP prolongation and shortening in response to 1 
µM BayK 8664 and 30 µM nifedipine (a calcium channel antagonist), 
respectively [90], [109].  
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3.1.2 Ion channel modulators 
 
BayK 8664 is a positive ionotrope that has been shown to increase APD by 
binding to L-type calcium channels and decreasing the activation time and 
shifting the voltage-dependence more negative [176], [177]. By affecting 
channel opening time and left-shifting the voltage dependence, there is a 
greater peak Ca2+ current at more negative membrane potentials, causing a net 
effect of an earlier, and greater ICaL current, and a more prolonged Ca2+ release 
from the sarcoplasmic reticulum (SR) during an AP [177], [178]. This means that 
BayK 8664 would prolong the APD90 by increasing the duration of the plateau 
phase, by increasing the probability of calcium channel opening from the shifted 
voltage-dependence, and decreasing the time of calcium channel activation. 
BayK 8664 has been shown to increase APD90 under standard electrode-based 
dynamic clamp conditions, so it is expected that ODC will yield the same effects 
[90], [109].  
 
Terfenadine is a H1-receptor antagonist and was marketed as an antihistamine. 
However, terfenadine was shown to be arrhythmogenic, after it was approved 
by the FDA and distributed to patients. It was discovered in post-market 
research that its mechanism of toxicity was through hERG channel antagonism 
and terfenadine was withdrawn from the market for cardiotoxicity [32], [179]–
[182]. Terfenadine is thought to bind within the central cavity of hERG and form 
crucial pi-pi stacking interactions, increasing its affinity to the channel [183]. 
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Terfenadine was one of the first drugs that led to the discovery that IKr inhibition 
is a potential mechanism behind drug-induced cardiac arrhythmia. Now, 
measuring IKr inhibition is an important focus during drug development to help 
predict drug-induced cardiac toxicity. In response to terfenadine, the APD90 will 
also be prolonged and the time of repolarization will be increased, since IKr is 
an important repolarizing current [174]. 
 
Verapamil is a clinically-approved drug to treat high blood pressure, severe 
angina and arrhythmias [184]–[186]. Verapamil binds to L-type calcium 
channels in a voltage- and use-dependent manner, thereby blocking calcium 
channels when open or inactivated at depolarized potentials [184], [187]. 
Verapamil also has a similar affinity to hERG channels as it does to calcium 
channels, and its binding to the channel is also state-dependent [188]. 
Interestingly, it is clinically safe in patients, despite also being a hERG channel 
blocker [185], [186], [189], [190]. The antagonistic effect of verapamil on calcium 
channels counteracts the prolongation of the action potential caused by hERG 
antagonism [191]. With the finding that drugs that inhibit IKr also tend to induce 
cardiac toxicity, drug developers are discouraged from pursuing the 
development of drugs that decrease IKr or have hERG affinity. Verapamil is a 
great example of a drug that would probably not be pursued for drug 
development today, but would be a missed opportunity for a safe and beneficial 
drug. In response to verapamil, the earlier phase of the AP (i.e., APD30) is 
shortened because of its effect on calcium channels, and averaging across 
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cells, APD90 does not change in a dose-dependent manner, although when 
looking at individual cells, both APD90 shortening and prolongation can be 
observed in cardiomyocytes of several species [174], [192]–[194].  
 
How iPSC-CMs under IK1 addition with EDC would respond to terfenadine and 
verapamil has not been investigated in the literature. iPSC-CMs may 
overestimate the effect of drugs that affect IKr, since iPSC-CMs have decreased 
levels of the other native repolarizing currents, IK1 and IKs. Perhaps with the 
addition of IK1, it could reduce this hypersensitivity to IKr inhibition. It will therefore 
be important to see the effects on AP characteristics of terfenadine and 
verapamil under dynamic clamp conditions compared to the control because of 
the addition of another repolarizing current. 
 
3.2 Materials and Methods 
 
3.2.1 Experimental protocol and analysis 
 
Preparation of ArchT-expressing iPSC-CMs, the electrophysiological protocol 
and the EDC and ODC platform protocols are described in the Materials and 
Methods section in Chapter 2. The analysis of AP characteristics was also 
calculated as described in the Materials and Methods section in Chapter 2. All 
cells and trials were included in the analysis, unlike in Chapter 2 where trials 
were not included in the analysis if they contained more than one spontaneous 
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event under EDC or ODC conditions. All cells had to be included here because 
spontaneous events occurred in some section of each protocol due to the 
shorter pacing frequency and longer protocol. APs were analyzed only if evoked 
by a stimulus (i.e., spontaneously occurring APs were not included in the 
analysis). 
 
3.2.2 Drug Screening Protocol 
 
After obtaining a whole-cell perforated patch, cells were paced at 0.5 Hz and 
APs were measured under control (no dynamic clamp), EDC, and ODC 
conditions, in no particular order, to establish a baseline. Three concentrations 
per drug were tested, from lowest to highest. After establishing the baseline AP 
by pacing the cells at 0.5 Hz under the three conditions without any drug 
present, the cells were perfused with an extracellular solution containing the 
drug for 5 minutes, and then the cells were paced again at 0.5 Hz and the APs 
were recorded. This was repeated with higher drug concentrations and APs 
were again measured under control, EDC, and ODC conditions, in no particular 
order. This protocol is illustrated in Figure 3.1. The drug concentrations used for 
BayK 8664 were 0 nM, 50 nM, 500 nM, and 5 µM. These concentrations were 
chosen to measure a dose-response effect, and 1 µM has been used with BayK 
8664 in iPSC-CMs to show that APD90 prolongation can be seen under IK1 
addition via dynamic clamp [102], [154]. Terfenadine was used at 0 nM, 50 nM, 
200 nM, and 500 nM. Verapamil was tested at 0 nM, 30 nM, 300 nM, and 3 µM. 
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The concentrations for terfenadine and verapamil used similar dose-response 
concentrations used in the literature [174]. For the remainder of the manuscript, 
“Drug None” refers to 0 nM of drug used, “Drug Low” refers to the smallest drug 
concentration used, “Drug Med” refers to the medium drug concentration used 
and “Drug High” refers to the highest drug concentration used.  
 
 
Figure 3.1: Illustration of the drug screening protocol 
After obtaining a perforated patch on an iPSC-CM (left panel), the cell was 
perfused with various concentrations of drugs sequentially and paced at 0.5 Hz 
under the three conditions listed in no particular order.  
 
 
 
3.3 Results  
 
3.3.1 Representative examples of cell response from dose 
response experiment under control, EDC and ODC conditions 
 
We analyzed the results from the drug screening experiments to determine how 
the ODC platform compared to the EDC platform, and if the platforms were still 
able to detect the anticipated changes on AP characteristics. The following 
figures illustrate an example of a cell that has undergone the drug screening 
protocol at the various concentrations of BayK 8664 (Figure 3.2), terfenadine 
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EDC  
ODC 
Pace 0.5 Hz 
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EDC  
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Drug Low 
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EDC  
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(Figure 3.3), or verapamil (Figure 3.4). The particular cells in Figures 3.2-3.4 
were chosen because they demonstrate how the tested cells typically respond 
during the drug screening protocol. Under control conditions, there is a greater 
amount of spontaneous activity that is inhibited with both EDC and ODC 
conditions, reducing the effect of AP rate dependence on subsequent AP 
characteristics. Similar to the effect seen in Figure 2.4, the membrane potential 
between APs are not always as well maintained in ODC as in EDC, and this is 
also reflected in Itarget (Figure 3.2A, 3.3 A-D). Looking at the resulting APs 
produced from the EDC and ODC platforms, the APs and Itarget under EDC and 
ODC conditions generally overlap well during the AP, indicating that the ODC 
condition can produce similar results to EDC. In addition, ODC is able to reflect 
similar effects of the drug on AP morphology under EDC conditions, such as 
APD90 prolongation with increasing BayK 8664 and terfenadine. Overall 
response to drugs under the EDC and ODC platforms will be further discussed 
in the next section.  
 
There are several cases where ODC does not overlap well with EDC during the 
AP (Figure 3.2A, 3.3A, 3.3D, and 3.4D). Similar to the results in Chapter 2, 
ArchT is unable to induce a negative current, unlike an electrode, so EDC is 
able to correct for the undershoot whereas ODC is unable to do so (Figure 3.3). 
The limitations of the ODC platform that could cause the mismatch of APs under 
ODC and EDC were described in Chapter 2 (Section 2.4.1) and are discussed 
further below (Sections 3.4.2 and 3.4.3). 
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In the results of Bett et al. (2013) the iPSC-CMs depolarized in the control in the 
presence of 1 µM BayK 8664 such that APs could not be stimulated and APs 
with a prolonged APD90 could only be successfully measured with dynamic 
clamp addition of IK1. However, this was not the case with BayK 8664 
administration in our experiments. The iPSC-CMs did not depolarize like the 
cells in Bett et al., and APs were still able to be stimulated. Unfortunately, 
because the AP-prolonging effect of BayK 8664 at Drug High was evident with 
and without dynamic clamp, we were unable to demonstrate the advantage of 
using dynamic clamp for drug screening.  
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Figure 3.2: Representative example of a cell under control, EDC and ODC 
conditions at different concentrations of BayK 8664  
The top panel illustrates two stimulated APs from an example cell exposed to 
various drug concentrations: Drug None (A), Drug Low (B), Drug Med (C), Drug 
High (D). The black triangles indicate when a stimulus current was delivered. 
The middle panels show the calculated Itarget (IK1). The bottom panels show the 
calculated light intensity used to generate the target current.  
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 Figure 3.2 (Continued) 
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Figure 3.3: Representative example of a cell under control, EDC and ODC 
conditions at different concentrations of terfenadine 
Figure is organized in the same manner as Figure 3.2.  
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Figure 3.3 (Continued) 
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Figure 3.4: Representative example of a cell under control, EDC and ODC 
conditions at different concentrations of verapamil 
Figure is organized in the same manner as Figure 3.2.  
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Figure 3.4 (Continued) 
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3.3.2 ODC platform can detect changes in AP characteristics in 
response to ion channel modulators  
 
To determine the feasibility of the ODC platform for drug screening, we need to 
confirm if the ODC platform can detect the effects of ion channel modulators on 
AP characteristics. The control condition verifies that the drug is active and the 
cell is responding as predicted. The EDC determines if under dynamic clamp 
conditions, the effect of the drugs on AP morphology is detectable with the 
addition of Itarget and is used to predict the effects the ODC platform should yield. 
Table 3.1 lists the average percent change of AP characteristics and SEMs of 
each drug tested and at each concentration. 
 
3.3.2.1 BayK 8664 
 
With increasing concentration of BayK 8664, we would expect APD30 and APD90 
to increase because of its effect on ICaL. Figure 3.5 illustrates the percent change 
in APD90, APD30, fraction of repolarization and triangulation, compared to the 
results within the same condition with Drug None, in response to treatment with 
BayK 8664 at different concentrations. An increase in APD90 is expectedly 
observed in the control, ODC and EDC conditions, but the increase in APD90 is 
statistically significant only at the highest concentration under control and ODC. 
The initial decrease of APD90, mainly seen in ODC, is not expected but not 
statistically significant. The reasons for this remain unknown. The control, EDC 
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and ODC demonstrate an average increase in APD30 but this is not statistically 
significant and there is a great variability of responses. There is one outlier in 
the ODC APD30 measurement, which could give the illusion that the outlier is 
responsible for the increased average APD30 with ODC. The average percent 
change in APD30 under ODC without the outlier is as follows: Drug Low, -1.8; 
Drug Med, 12.2%; Drug High, 23.3%. Even without the outlier, there is an 
increase in percent change of APD30. The decrease in average triangulation and 
fraction of repolarization is reflected by the increase in APD30 but not APD90, 
and is not statistically significant. The activity of BayK 8664 used in these 
experiments had previously been confirmed with calcium imaging experiments 
with Fluo 4-AM with guinea pig cardiomyocytes (data not shown). The results of 
the drug-screening experiments were not due to inactivity of BayK 8664. 
 
3.3.2.2 Terfenadine 
 
Terfenadine, like BayK 8664, is expected to prolong the APD90 because of its 
effect on IKr. Because the drug is inhibiting a major repolarizing current, it is also 
expected that the fraction of repolarization and triangulation will both increase. 
Figure 3.6 displays the percent change of AP characteristics at different 
concentrations of terfenadine under control, EDC and ODC conditions. There is 
an unexpected but not statistically significant decrease in APD90 at Drug Low, 
followed by a dose-dependent increase in APD90 at Drug Med and High (only 
statistically significant at Drug Med in Control, and Drug High in all three 
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conditions). APD30 interestingly shortened at all drug concentrations in all three 
conditions, but less drastically in ODC. The decrease in APD30 was statistically 
significant in Control and EDC at Drug Low. The reason for this is unknown, but 
the effect could cause the initial decrease in APD90. Perhaps greater IKr 
inhibition at higher drug concentrations was able to overcome this unknown 
effect and prolong APD90. All three conditions expectedly yielded a significant 
increase in fraction of repolarization and triangulation in a dose-dependent 
manner after the initial decrease in APD90. This demonstrates that the ODC 
platform is sensitive to IKr inhibition, which is crucial for future drug screening 
applications given its significance in predicting drug-induced cardiovascular 
toxicity.  
 
3.3.2.3 Verapamil 
 
Finally, unlike the other two drugs, verapamil affects two different ionic currents. 
With Ca2+ channel antagonism, APD90 and APD30 would shorten, and 
triangulation would increase. IKr inhibition would typically prolong APD90 and 
fraction of repolarization. Previous literature has demonstrated that as a net 
effect of both Ca2+ channel antagonism and IKr inhibition, APD90 does not 
typically change on average, but when looking at individual cells, a variety of 
effects on APD90 can be measured [174]. This is because individual cells with a 
net effect of shortening, prolonging, or not changing the APD90 may result from 
the varying contribution of ICaL and IKr on the level of the individual cell to APD. 
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But when averaged across all cells, APD90 does not get prolonged in a dose-
dependent manner despite inhibiting hERG channels, which is presumably why 
verapamil is safe for patients.  
 
In the results of the verapamil screen (Figure 3.7), shortening of the APD30 in a 
dose-dependent manner can be observed in control, EDC and ODC conditions. 
Averaging across all cells, the APD90 initially shortens at lower drug 
concentrations and then increases back to baseline (Drug None). This 
observation is consistent to the opposing effects of IKr and ICaL inhibition and 
consistent with what is seen in literature [93], [195]. APD30 decreases in a dose-
dependent manner, presumably resulting from the ICaL inhibition. Fraction of 
repolarization and triangulation all increase in a dose-dependent manner, as 
expected, under all three platform conditions [174]. The changes in fraction of 
repolarization and triangulation suggests inhibition of IKr. This demonstrates that 
the ODC platform can also reflect the overall effect of drugs that have multiple 
targets on AP characteristics.  
 
In summary, the ODC platform is able to measure the expected changes in AP 
characteristics in response to various well-characterized ion channel 
modulators. This suggests the potential reliability of the ODC platform in drug 
screening applications.  
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Figure 3.5: Effect of BayK 8664 at different concentrations on AP 
characteristics under Control, EDC and ODC conditions 
Average and SEM percent change of several AP characteristics: APD90 (A), 
APD30 (B), Fraction of Repolarization (C) and Triangulation (D) at different drug 
concentrations. The gray, orange, and green points represent the results under 
control conditions, with EDC, and with ODC, respectively. The blue points 
represent individual cells. 
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Figure 3.6: Effect of terfenadine at different concentrations on AP 
characteristics under Control, EDC and ODC conditions 
Figure is organized in the same manner as Figure 3.4. 
n = 5 
* p < 0.05 compared to Drug None of the same condition (Control, EDC or ODC)  
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Figure 3.7: Effect of verapamil at different concentrations on AP 
characteristics under Control, EDC and ODC conditions 
Figure is organized in the same manner as Figure 3.4. 
n = 9 
* p < 0.05 compared to Drug None of the same condition (Control, EDC or ODC)  
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Table 3.1: Average percent change relative to Drug None and SEM values 
of AP characteristics during drug screening protocol 
 
 
 
 
  
APD90   
Control EDC ODC   
Average SEM Average SEM Average SEM 
BayK 8664 Low 5.8 12.0 0.8 6.2 -7.9 5.0 
Med 1.3 3.8 12.1 7.3 2.4 5.8 
High 19.6 3.0 21.6 9.3 22.8 6.8 
Terfenadine Low -6.9 3.3 -11.5 5.1 -0.2 9.4 
Med 10.4 2.5 5.6 6.2 17.7 11.6 
High 22.3 3.2 24.0 6.6 39.3 17.9 
Verapamil Low -13.2 2.8 -11.5 2.7 -11.5 4.4 
Med -9.9 4.0 -7.7 4.5 -6.4 5.1 
High 2.9 8.5 4.9 9.1 7.7 10.9 
 
  
APD30   
Control EDC ODC   
Average SEM Average SEM Average SEM 
BayK 8664 Low 26.2 27.0 12.2 15.9 35.4 38.2 
Med 11.5 8.1 22.5 16.4 65.5 54.4 
High 29.0 12.1 22.9 20.4 96.7 76.5 
Terfenadine Low -11.5 3.2 -15.5 5.4 -7.0 4.3 
Med -9.6 4.6 -10.7 4.8 -1.6 4.9 
High -15.1 6.9 -7.5 4.9 0.2 8.9 
Verapamil Low -18.3 3.6 -15.4 3.0 -14.8 6.2 
Med -25.3 4.4 -21.3 2.9 -21.5 3.9 
High -31.2 6.3 -25.1 5.5 -22.5 6.3 
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Fraction of Repolarization   
Control EDC ODC   
Average SEM Average SEM Average SEM 
BayK 8664 Low -9.3 6.9 -11.4 8.9 -7.1 9.3 
Med -10.9 4.4 -15.7 8.9 -15.2 8.7 
High 7.3 24.7 26.8 50.8 48.8 70.4 
Terfenadine Low 9.9 2.4 9.8 2.5 17.1 14.1 
Med 37.7 4.7 33.6 4.7 37.6 14.2 
High 76.1 8.3 65.1 11.5 71.7 17.4 
Verapamil Low 18.4 6.7 12.4 5.0 17.4 6.4 
Med 42.1 11.4 39.5 8.6 46.0 8.7 
High 96.2 23.2 77.5 15.0 75.7 14.2 
 
  
Triangulation   
Control EDC ODC   
Average SEM Average SEM Average SEM 
BayK 8664 Low -12.3 7.4 -3.8 3.9 -11.8 9.5 
Med -8.5 5.8 1.3 6.0 -9.4 9.4 
High 17.7 18.0 30.2 19.0 54.0 56.2 
Terfenadine Low 1.6 3.6 -2.9 3.9 13.8 20.6 
Med 45.8 7.3 38.3 7.0 55.1 28.2 
High 90.9 4.5 89.2 8.6 115.3 42.9 
Verapamil Low -1.5 4.4 -3.6 5.4 -1.8 6.1 
Med 18.7 6.9 20.0 10.7 23.4 10.4 
High 67.6 22.0 57.5 15.3 61.8 19.8 
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3.3.3 Comparing the effect of EDC and ODC on AP characteristics 
during drug screening 
 
After demonstrating that the ODC platform can detect the expected drug-
induced changes in AP characteristics, the accuracy of the ODC platform to 
yield similar results to the EDC platform must be investigated. Based on the 
results in Chapter 2, it is expected that APD90 would be shortened, and the 
fraction of repolarization and triangulation would also decrease when dynamic 
clamp is applied compared to the control without dynamic clamp. Ideally, it is 
also expected that ODC yield the same results to EDC, but based on the results 
in Chapter 2, ODC may not change AP characteristics by the same magnitude 
as EDC. Nonetheless, it should yield a similar positive or negative effect as 
EDC. Differences in the results between the ODC and EDC could be due to 
limitations to using ArchT or inaccuracies of the ArchT model used to calculate 
the light intensity. These were elaborated upon in the Discussion section of 
Chapter 2. Table 3.2 lists all the averages of AP characteristics and SEMs of 
each drug tested and at each concentration. 
 
Figure 3.8 displays the average and standard error of the mean (SEM) of AP 
characteristics in control, EDC and ODC at different drug concentrations with 
bayK 8664 administration. EDC is able to produce the expected results on APD 
as stated above in most cases. EDC did not yield an expected decrease fraction 
of repolarization and only a modest decrease in triangulation was achieved. The 
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APD90 and APD30 of APs resulting from the ODC platform is similar to EDC in 
most cases (except APD90 at Drug None and Drug High). Looking at fraction of 
repolarization and triangulation, the results from ODC were not similar to EDC. 
ODC was more similar to the results from control, and sometimes were different 
from both control and EDC. The potential reasons as to why ODC did not 
perform as well as EDC are further discussed in the Discussion section.  
 
In the presence of terfenadine, the EDC platform shortened the APD90, and 
decreased fraction of repolarization and triangulation, as expected at different 
drug concentrations (Figure 3.9). ODC had a similar effect on these parameters 
as EDC, but not to the same magnitude as EDC did. This suggests that although 
ODC does affect AP characteristics as expected with dynamic clamp addition 
of Itarget, it does not behave identically to an electrode.  
 
In Figure 3.10, results from the drug screen with verapamil shows that EDC 
decreased APD90, fraction of repolarization and triangulation, as expected with 
dynamic clamp. But as was the case with terfenadine application, ODC has a 
similar effect as EDC on AP characteristics, but it did not have the same 
magnitude of an effect as EDC. This supports the idea that the ODC platform is 
able to affect AP characteristics, but it does not behave identically to EDC.   
93 
 
 
 
 
Figure 3.8: Comparing the average effect of bayK 8664 on AP 
characteristics between Control, EDC and ODC  
Average and SEM of several AP characteristics: APD90 (A), APD30 (B), Fraction 
of Repolarization (C) and Triangulation (D) at different drug concentrations. The 
gray, orange, and green points represent the results under control conditions, 
with EDC, and with ODC, respectively. The blue points represent individual 
cells. 
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Figure 3.9: Comparing the average effect of terfenadine on AP 
characteristics between Control, EDC and ODC 
Figure is organized in the same manner as Figure 3.8. 
n = 5 
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Figure 3.10: Comparing the average effect of verapamil on AP 
characteristics between Control, EDC and ODC 
Figure is organized in the same manner as Figure 3.8. 
n = 9 
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Table 3.2: Average and SEM values of AP characteristics during drug 
screening protocol 
 
 
  
APD90 (msec)   
Control EDC ODC   
Average SEM Average SEM Average SEM 
BayK 8664 None 334.9 41.4 287.7 41.8 316.4 39.6  
Low 339.5 35.3 280.2 31.4 283.6 28.1  
Med 339.5 45.7 316.1 42.0 324.1 47.1 
High 402.3 55.2 328.4 23.5 394.2 66.6 
Terfenadine None 337.9 29.0 302.7 21.6 307.6 35.9  
Low 314.8 28.5 266.2 18.3 299.1 31.9  
Med 373.8 35.9 319.9 29.2 350.2 26.1 
High 407.1 27.6 375.1 30.8 409.6 32.7 
Verapamil None 343.3 31.2 313.3 31.4 324.5 33.9  
Low 298.3 29.9 274.9 24.9 284.9 29.5  
Med 311.6 37.0 288.2 31.7 301.1 32.1 
High 361.3 53.9 319.3 29.5 341.6 39.3 
 
  
APD30 (msec)   
Control EDC ODC   
Average SEM Average SEM Average SEM 
BayK 8664 None 191.6 35.1 177.4 38.1 172.2 41.3  
Low 214.7 32.5 169.7 24.8 161.8 27.1  
Med 208.7 36.9 201.0 34.7 199.7 46.2 
High 225.9 23.5 178.2 29.7 178.0 29.9 
Terfenadine None 219.5 22.3 205.4 22.1 199.8 23.5  
Low 193.5 17.6 171.1 15.4 183.3 19.1  
Med 200.6 29.1 183.5 23.0 194.2 21.7 
High 184.4 19.6 189.5 21.7 195.7 21.1 
Verapamil None 221.8 25.3 203.4 28.7 207.0 28.7  
Low 175.3 20.5 169.3 21.4 170.9 22.1  
Med 163.7 23.6 160.0 23.9 160.6 20.7 
High 150.3 20.5 146.2 16.1 153.9 17.7 
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Fraction of Repolarization   
Control EDC ODC   
Average SEM Average SEM Average SEM 
BayK 8664 None 0.29 0.03 0.32 0.07 0.34 0.07  
Low 0.26 0.03 0.25 0.03 0.29 0.04  
Med 0.26 0.03 0.23 0.03 0.27 0.04 
High 0.29 0.04 0.28 0.06 0.32 0.06 
Terfenadine None 0.21 0.02 0.18 0.02 0.20 0.02  
Low 0.23 0.02 0.20 0.02 0.23 0.02  
Med 0.29 0.03 0.24 0.03 0.27 0.03 
High 0.37 0.03 0.30 0.03 0.34 0.03 
Verapamil None 0.21 0.02 0.20 0.02 0.21 0.03  
Low 0.25 0.02 0.22 0.02 0.24 0.03  
Med 0.31 0.03 0.27 0.02 0.29 0.03 
High 0.41 0.04 0.34 0.04 0.35 0.04 
 
  
Triangulation (msec)   
Control EDC ODC   
Average SEM Average SEM Average SEM 
BayK 8664 None 143.3 12.5 115.5 15.0 144.2 21.3  
Low 124.9 13.9 110.5 12.2 121.8 12.0  
Med 130.8 13.4 115.1 11.9 124.4 11.1 
High 176.4 42.1 150.2 35.3 216.3 86.9 
Terfenadine None 118.4 11.8 97.3 7.2 107.8 15.5  
Low 121.3 15.2 95.1 9.8 115.8 17.3  
Med 173.1 20.3 136.3 15.9 156.1 13.9 
High 222.7 22.4 185.6 19.2 213.8 22.0 
Verapamil None 121.5 11.4 109.9 8.3 117.6 11.8  
Low 123.0 13.3 105.6 9.4 114.0 11.5  
Med 147.9 17.5 128.2 10.8 140.5 15.7 
High 211.0 38.9 173.1 21.5 187.7 27.9 
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Pre-Stimulation Potential (mV)   
Control EDC ODC   
Average SEM Average SEM Average SEM 
BayK 8664 None -69.9 2.8 -70.3 1.7 -67.6 2.5 
Low -67.2 2.1 -68.8 1.8 -65.7 1.7 
Med -67.0 2.7 -70.3 2.2 -67.4 2.8 
High -68.7 3.2 -69.2 2.0 -67.4 1.8 
Terfenadine None -74.0 2.4 -73.3 1.4 -73.0 2.1 
Low -70.6 2.4 -69.6 2.2 -68.9 2.3 
Med -66.6 2.2 -69.7 1.3 -67.3 2.2 
High -63.1 2.2 -69.0 1.7 -64.6 1.4 
Verapamil None -70.5 3.0 -71.7 2.3 -71.9 1.9 
Low -66.9 2.5 -70.5 1.6 -69.4 2.1 
Med -65.7 1.6 -69.2 1.4 -66.9 1.8 
High -62.2 2.2 -69.5 1.3 -67.9 1.2 
  
99 
 
3.4 Discussion 
 
3.4.1 ODC platform reveals effects of ion channel modulation on 
AP characteristics but does not replicate EDC results 
 
The ODC platform can yield overlapping results from the EDC platform, but not 
consistently (Figures 3.2-3.4). The dose-response experiments screening BayK 
8664 demonstrated a significant APD90 prolongation only at the highest drug 
concentration. (Figures 3.5, Table 3.1). The dose-response experiments with 
terfenadine yielded a dose-dependent increase in APD90, fraction of 
repolarization and triangulation (Figure 3.6, Table 3.1). In addition, there was 
no difference in sensitivity to the drug when IK1 was simulated with dynamic 
clamp conditions. Dose-response experiments with verapamil demonstrated 
APD30 shortening, increase in triangulation and increase in fraction of 
repolarization in a dose-dependent manner (Figure 3.7, Table 3.1). APD90 did 
not change in a dose-dependent manner, as anticipated.  
 
ODC generally had a similar effect (e.g., increasing or decreasing) on AP 
characteristics as EDC, but did not have the same magnitude of an effect on AP 
characteristics as the EDC platform (Figures 3.8-3.10). In addition, even though 
the ODC platform results sometimes overlaps with the EDC results, this may 
not happen throughout the entire protocol with a specific cell (Figures 3.5-3.7). 
This reveals a concern and implies that something is hindering the ODC 
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platform performance. There are a number of potential causes. First, as 
previously mentioned in Chapter 2, the ArchT model used to calculate the light 
intensity could be limited and so we are not generating the target current that 
we are predicting with our model. Second, there may be downstream 
consequences of using opsins, which would prevent ODC from exactly 
mimicking an electrode. This is further elaborated in in Section 3.4.3.  
 
3.4.2 Limitation in analysis of AP characteristics  
 
Calcium-handling abnormalities of iPSC-CMs could be another potential reason 
that obscures the success of the BayK 8664 drug screen. As briefly described 
in Section 1.4, iPSC-CMs have abnormal spontaneous calcium release, which 
underlies spontaneous activity, and they also lack T-tubules. The lack of T-
tubules prevents the co-localization of membrane calcium channels and 
ryanodine receptors (RyR), thus preventing the coordinated intracellular calcium 
release typical of adult ventricular cardiac myocytes [76]. The subcellular 
spontaneous calcium release underlying spontaneous activity signifies the lack 
of coordination between voltage and calcium release and the immature calcium 
handling properties. One potential mechanism of how spontaneous calcium 
release leads to a spontaneous event is that the SR activates the sodium 
calcium exchanger (NCX) until the threshold is reached and an AP is initiated 
[80]. The lack of coordination between ICaL and RyR could blunt the response to 
BayK 8664. A 20% increase in APD90 was observed in our experiments, but a 
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prolongation of about 30% and 200% was seen with 1 µM Bay K8664 in other 
papers that used dynamic clamp to mimic IK1 [102], [154]. This is indicative of 
inter-lab differences of iPSC-CMs, which will be addressed again later in this 
section. Perhaps in our experiments, ICaL agonism caused by BayK 8664 at 
lower concentrations is less coordinated with RyR activation and unable to 
trigger as much calcium-induced calcium release (CICR) and thus APD90 is not 
significantly prolonged until higher concentrations.  
 
We speculate that in the iPSC-CMs used in the experiments presented in 
Chapter 3, ICaL does not greatly contribute to APD90 because strong repolarizing 
currents are present, perhaps IK1. In the experiments conducted, the pre-
stimulation potential (Table 3.2) did not change between different 
concentrations of BayK 8664 in any of the three conditions. In contrast, 1 µM 
BayK 8664 greatly depolarized the MDP  [154]. In the automated patch clamp 
experiments injecting a different formulation of IK1 in iPSC-CMs conducted by 
Goversen et al., a greater maximum conductance was used, pushing the resting 
membrane potential to -94 mV. Perhaps this was able to better suppress 
spontaneous calcium release and thus spontaneous activity compared to our 
experiments; the potential influence of spontaneous activity will be discussed 
later on in this section. IK1 addition via dynamic clamp may be necessary for 
pushing iPSC-CM electrical maturity but not sufficient when there are other 
important components missing. IK1 expression suppresses spontaneous activity 
by making iPSC-CMs less prone to reaching a threshold, but it is dysregulated 
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calcium release that triggers spontaneous APs [80], [196]. Cyclical spontaneous 
calcium release can push calcium channels into a refractory period and 
decrease the time for the SR to refill its Ca2+ stores, such that the resulting 
calcium transient is shorter in duration and amplitude [197]. The dysregulation 
of the iPSC-CM calcium system and its consequences on the ability of iPSC-
CM to reflect adult cardiomyocyte behavior needs to be further investigated. 
After these experiments were performed, unfortunately a literature search with 
a slightly different spellings of BayK 8664 (Bay K8664 and Bay K 8664) revealed 
that iPSC-CMs in different labs were able to expectedly prolong APD90 with 1 
µM BayK 8664 [198], [199]. To make matters more confusing, there are also 
other labs that used BayK 8664 and concluded that BayK 8664 did not see an 
increase the calcium current in iPSC-CMs [200], [201]. In hindsight, BayK 8664 
was not the best drug to test with the purpose of demonstrating an advantage 
of dynamic clamp. Given the variability of responses of iPSC-CMs to BayK 8664 
in different labs, this would not be an ideal drug candidate to demonstrate the 
benefits of dynamic clamp and to test the ability of iPSC-CMs under the ODC 
platform to respond to ion channel modulators. In addition, perhaps the 
concentrations chosen for the dose-response experiments should be increased.  
 
The results of Chapter 2 were interpreted from trials and cells that did not 
contain more than one spontaneous event under EDC or ODC. The cells used 
in Chapter 3 were spontaneously active, which when combined with the slower 
pacing frequency of 0.5 Hz, makes it difficult to outpace the intrinsic rate of 
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spontaneous activity (Figures 3.2 and 3.3), whereas in Chapter 2, faster pacing 
frequencies prevented the occurrence of spontaneous events. Cardiomyocyte 
APs are affected by the rate of AP firing, both stimulated and spontaneous. The 
presence of spontaneous events is problematic because these sporadic events 
affect the AP morphology of the subsequent event, thereby skewing the 
measured AP characteristics. The proximity of a spontaneous event prior to a 
stimulated AP can stunt the amount of ionic channel activation because they 
may not have recovered from the spontaneous event. The closer the prior event, 
the less recovery time there is for voltage-gated channels, thus affecting the AP 
characteristics of the subsequent event (i.e., smaller APD, shorter APA) [202], 
[203]. In other words, the morphology and quantitative features such as APD of 
a stimulated AP without a proximal prior spontaneous event would be different 
from those of a stimulated AP with a proximal prior spontaneous event. This is 
typically observed in native cardiomyocytes and is known as restitution. 
Because of this, it is not fully accurate to compare EDC and ODC when there 
are spontaneous events present.  Unfortunately, we are unable to analyze trials 
without any spontaneous events because all trials had spontaneous events 
during some portion of the protocol. Figure 3.11 displays the average rate of 
spontaneous activity of different drugs, at different concentrations and in 
different conditions. The average rate of spontaneous activity generally exceeds 
the pacing frequency, making it inevitable to analyze cells with spontaneous 
activity. As previously seen in Chapter 2 and again seen in Chapter 3, dynamic 
clamp tends to suppress the rate of spontaneous activity, demonstrating an 
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advantage of dynamic clamp (Figures 2.4, 2.6, 3.2-3.4, 3.11, Appendix A3). The 
rate and timing of spontaneous activity prior to a stimulated AP in EDC and ODC 
is not identical across cells, between conditions, or across drug concentrations. 
This prevents a clean comparison between the EDC and ODC results and 
across drug concentrations. This is a limitation in the analysis, which can be 
overcome with non-spontaneously active iPSC-CMs. Unfortunately, given the 
current nature of iPSC-CM derivation, spontaneously active iPSC-CMs are 
selected for patching because the researcher is confident that the cell was 
successfully differentiated into a cardiomyocyte, albeit an immature one.  
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Figure 3.11: Average rate of spontaneous activity under Control, EDC and 
ODC conditions at different drug concentrations of BayK 8664, 
terfenadine and verapamil 
Average and SEM of rate of spontaneous events under control, EDC and ODC 
conditions with (A) BayK 8664, (B) terfenadine and (C) verapamil at different 
drug concentrations. The gray, orange, and green bars represent the results 
under control conditions, with EDC, and with ODC, respectively.  
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3.4.3 The ODC platform in more mature and relevant formats 
 
There is a myriad of abnormalities in iPSC-CMs that can decrease its relevance 
to adult cardiomyocytes. It is difficult to pinpoint what is the highest priority to 
address but it will be revealed as differentiation techniques that mimic cardiac 
development are discovered. A disadvantage of the current ODC 
implementation is that it requires single cells. Not only is the relevance of single 
cells limited, but also single cells have less markers of maturity than monolayers 
[165], [204]. The ODC platform has the potential to be used in monolayers, 
unlike EDC. This format would incorporate electrical coupling properties into the 
in vitro model, and the iPSC-CMs would be inherently more mature. In addition, 
the ODC platform does not need to use a monolayer exclusively composed of 
iPSC-CMs but can also include other cardiac cell types (i.e., cardiac fibroblasts, 
endothelial cells) and further promote maturity by mimicking cardiac 
development [205], [206]. The ODC platform would mimic a current of interest 
and allows for spatial resolution, opening a door to expand experimental 
possibilities to enable the power of dynamic clamp in many different types of 
cardiac tissue-like preparations. 
 
3.4.4 Conclusion 
 
This chapter first aimed to demonstrate the feasibility of the ODC system to be 
used for drug screening. The failure of ODC to replicate EDC results is not ideal, 
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but as described above, may not be due to the inability of optogenetics to 
precisely inject a target current. The success of ODC to demonstrate some of 
the effects of ion channel modulators suggests it may still be useful for drug 
screening, but with limitations. The possibilities of the ODC platform (e.g., using 
dynamic clamp in monolayers, using dynamic clamp in co-cultures, generating 
currents driven by a specific ionic species) may outweigh the drawbacks 
(decreased precision of injecting a target current). The second aim of the 
chapter was to demonstrate an advantage of dynamic clamp addition of IK1, but 
unfortunately, no benefit to using dynamic clamp to add IK1 was demonstrated. 
Surprisingly the cells were able to detect Ca2+ agonism without dynamic clamp, 
contrary to the results in another lab [154]. This highlights the problem of inter-
lab or iPSC source and batch variability [207]. Another reason could be that 
supplementing the lack of IK1 is not as important to produce an adult 
electrophysiological phenotype in iPSC-CMs. Genetic expression of IK1 alone 
does not solve the problem of electrical immaturity [196]. As mentioned in 
Section 3.4.2, abnormal calcium dynamics also underlies abnormal behavior. 
Other abnormalities, i.e., ultrastructural, protein expression, etc. mentioned in 
Section 1.4 also have global consequences that could limit the extent iPSC-
CMs can behave like an adult cardiomyocyte. Further development is needed 
before ODC can be confidently used in lieu of an electrode-based system, but 
the current ODC platform is an important first step that provides a proof-of-
concept of using optogenetics in a fully optically-controlled dynamic clamp 
system for drug screening.  
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CHAPTER FOUR 
 
CONCLUSIONS AND FUTURE DIRECTIONS  
 
4.1 Summary 
 
4.1.1 Optogenetics as a tool to inject a dynamically-changing 
target current 
 
Optogenetic tools have been previously used to statically stimulate electrical 
activity using depolarizing opsins or inhibit electrical activity using 
hyperpolarizing opsins. This has been fruitful to dissect neurological pathways 
by stimulating or inhibiting specific regions of the brain [149], [150], [208]–[214]. 
In cardiology, the idea of using optogenetics as a replacement for a pacemaker 
has been proposed [143], [171], [172], [215]–[217]. Optogenetics were also 
used to inhibit specific regions in the zebrafish heart to identify the pacemaker 
cells or which cells to stimulate that elicited a desired response (i.e., 
tachycardia, bradycardia, atrioventricular blocks, and cardiac arrest) [215]. 
Optogenetics and iPSC-CMs are also being combined in the hopes of 
developing all-optical electrophysiology that can current clamp, voltage clamp, 
and measure calcium transients [117], [133]–[137], [170], [208]. In this thesis, 
we aim to demonstrate a proof-of-concept where we can precisely control 
opsins to produce a dynamically-changing current of interest based on real-time 
feedback from voltage input for drug screening applications. 
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4.1.1.1 Gaining control of ArchT to generate a dynamic current 
 
Of the hyperpolarizing tools available, we chose ArchT because of its fast 
kinetics, which is necessary for the real-time requirements of dynamic clamp. 
As discussed in Chapter 2.4.1., an opsin whose activation and deactivation 
kinetics are less than 60 msec would not compromise the real-time feedback 
loop (Appendix A11) [89]. There are currently more enhanced versions of ArchT 
(e.g. eArchT) that can generate a larger photocurrent if the user wanted to 
generate a larger current that exceeds the limit of 1.08 pA/pF that was imposed 
in the experiments conducted. Even though the ODC platform was developed 
using ArchT, it would be feasible to use many optogenetic proteins, as long as 
there is a mathematical model available to calculate the light intensity needed 
to activate the opsin and generate a target current. This flexibility is important, 
as more opsins are being developed to be faster, more specific for certain ions, 
and produce a larger photocurrent.  
 
To control our selected opsin to generate a specified current, we would first 
need to understand how ArchT behaves, describe it in a mathematical model, 
and then use the mathematical model to predict the conditions needed to 
generate the specified current. The model developed for ArchT (Eq. 2.1) was 
built to predict what current would be produced, given the Vm and the light 
intensity, not based on the structural mechanism of ArchT activation.  
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To investigate the light-intensity dependence, the iPSC-CMs were voltage 
clamped at various holding potentials (mV): -100, -60, -20 and 20 (Figure 4.1). 
At each holding potential, the cells were then “light clamped”, meaning they 
were illuminated at various LED outputs, with 5V being the maximum (Figure 
4.1A). The amount of current produced at different light intensities was 
measured. Figure 4.1B illustrates the normalized results from individual cells. 
This shows the heterogeneity of the light-dependence behavior of ArchT in 
different cells and the need for a cell-specific ArchT model to precisely calculate 
the light intensity needed. Figure 4.1C illustrates the average and SEM of the 
normalized current produced at a different LED outputs across all cells. The 
equation, b1 �1 −   e−b2 ∙Ee�, can be used to describe the light-intensity 
dependence relationship. To address the heterogeneity of the light-dependence 
behavior, the parameters of the light-dependence equation, b1 and b2, can be 
determined for each cell with the calibration protocol and thus the light-
dependence component of the ArchT equation can be tailored to the individual 
cell (Figure 2.2). Figure 4.1D plots the average light-dependence at different 
holding potentials. This ensures that despite the voltage sensitivity of ArchT, the 
light-dependence relationship remains consistent across different holding 
potentials. These experiments informed us on how to build the light-intensity 
dependence of the ArchT model (Eq. 2.1).  
 
The voltage dependence of ArchT was also investigated with voltage clamp and 
light clamp experiments, by illuminating the cells with the same light intensity at 
111 
 
different holding potentials (Figure 4.2A). Figure 4.2B displays the normalized 
ArchT current produced at different holding potentials in individual cells. The 
results also demonstrate a great heterogeneity of voltage dependence between 
cells. This further bolsters the need for a cell-specific ArchT model (Figure 4.2B). 
A linear model would be apt to describe the voltage dependence of ArchT and 
the parameters can be measured in a specific cell using the calibration protocol 
(Figure 4.2C). The voltage-dependence term of the ArchT mathematical model 
behaves like a scaling factor to the light-intensity dependence.  
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Figure 4.1: Investigating light-intensity dependence of ArchT  
The cells were illuminated for 1 second with 1 second light off in between. The 
cells were held at -100 mV, then the light clamp protocol would illuminate the 
cells at 0.05 V, 0.1 V, 0.3 V, 0.5 V, 1 V, 3 V, 5 V LED output, which translates 
to 0.005, 0.01, 0.03, 0.05, 0.1, 0.3, 0.5 mW/mm2 light intensities (A).  
The normalized traces of the results from the protocol in (A) in individual cells 
are displayed (B).  
(C) illustrates the average and the SEM. The red line demonstrates the power 
equation used to fit the light-intensity dependence of ArchT.  
The normalized light-dependence relationship at different holding potentials 
were averaged (D).  
 
n = 26  
A B 
C D 
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Figure 4.2 Investigating voltage dependence of ArchT  
The cell was illuminated at 5V LED output (0.5 mW/mm2) for 1 second three 
times with 1 second of light off in between each light pulse while being held at -
100 mV, -80 mV, -60 mV, -40 mV, -20 mV, 0 mV, 20 mV, and 40 mV (A). The 
normalized traces displaying the results of the protocol of individual cells are 
displayed (B). The average and SEM of the traces are displayed and the red 
line displays the linear model used to describe the average voltage dependence 
(C).  
 
n = 26  
A 
B 
C 
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4.1.1.2 Using ArchT to generate a dynamic current 
 
Chapter 2 presents how to obtain a cell-specific ArchT model using a calibration 
protocol and use it to dynamically generate a target current in iPSC-CMS in a 
real-time feedback loop. This was demonstrated by mimicking IK1 in iPSC-CMs 
and comparing the results to using an electrode. IK1 was chosen because iPSC-
CMs have reduced IK1 and addition of IK1 improved electrophysiological maturity 
[22], [87], [102], [107], [154], [196]. Chapter 2 revealed that ArchT could be 
dynamically controlled to generate a target current. Looking at individual cells, 
there were cells where the ODC platform mimicked the EDC platform nearly 
identically, but there were also some cases where ODC affected AP 
characteristics similarly to EDC but not to the same magnitude. The reason for 
this discrepancy remains unknown. Possible reasons, as previously discussed 
in Section 2.4.1, include the type of opsin chosen has unknown downstream 
consequences, or the ArchT model needs to be improved for more accuracy.  
 
After demonstrating a proof-of-concept of controlling opsins to dynamically 
generate a target current, we wanted to test how the platform responds to IKr 
inhibition by administering E-4031 to demonstrate its applicability for preclinical 
drug development. With E-4031 administration, the APD90 was prolonged, as 
expected, in control, EDC and ODC conditions compared to the same condition 
without drug. Both EDC and ODC shortened the APD90 compared to the control 
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and the stimulated APs between ODC and EDC had similar AP characteristics. 
This demonstrates that the ODC platform is also able to detect similar effects 
as the standard EDC method when challenged with IKr inhibition, which is 
currently used during drug development as an important factor to predict 
potential cardiovascular toxicity in patients. 
 
4.1.2 Using the ODC platform for drug screening 
 
In the context of drug discovery, optogenetics have been used to automate high-
throughput assays. Replacing traditional patch clamp methods with 
optogenetics to make these useful techniques more accessible and high-
throughput is of great interest for drug-discovery purposes. Currently, methods 
to simultaneously stimulate and image multiple cells to optically current clamp, 
and methods to hold the membrane potential to optically voltage clamp are 
being developed [117], [129], [143], [144], [218]. There are also different 
platforms being developed or adapted to incorporate LEDs that enables the use 
of optogenetics in a high-throughput manner, through automated imaging 
and/or stimulating multiple wells simultaneously [117], [120], [159], [173], [219].  
 
Chapter 3 aims to investigate how the ODC platform performs in the presence 
of ion-channel modulators. Terfenadine, verapamil, and BayK 8664 were tested. 
Similar to the results in Chapter 2, the ODC platform performed identically to 
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EDC in some cases and did not mimic EDC in some cells. The iPSC-CMs under 
control, EDC and ODC conditions responded as anticipated to terfenadine and 
verapamil in Chapter 3, demonstrating some potential for the ODC platform to 
be used for drug screening. The use of BayK 8664 in the experiments executed 
in Chapter 3 was meant to demonstrate a benefit to using the dynamic clamp 
platform, since the effects should only be observed with addition of IK1 via 
dynamic clamp. However, results with BayK 8664 were more inconclusive and 
the expected result was only observed at the highest drug concentration.  iPSC-
CMs also have varying responses to BayK 8664 across labs [154], [199]–[201], 
[220], [221]. Both dynamic clamp platforms were unable to demonstrate a 
benefit over the control when challenged with BayK 8664. Reasons for this were 
discussed in Section 3.4.2. Bett et al. (2013) had demonstrated that the effects 
of BayK 8664 were detectable only under dynamic clamp conditions [154]. 
Unfortunately, the benefit of IK1 addition was not reproduced in this work 
because the effect of BayK 8664 was detected without IK1 addition. The iPSC-
CMs used in Chapters 2 and 3 were more hyperpolarized than the iPSC-CMs 
in Bett et al. (2013) and did not depolarize significantly in the presence of BayK 
8664, so APs could still be successfully stimulated and the effects of BayK 8664 
could be detected under control conditions. Given how iPSC-CMs in our 
experiments and from other published work cannot consistently recapitulate the 
effect of how native cardiomyocytes respond to BayK 8664 suggests that our 
results may be due to the immaturity of iPSC-CMs, rather than a reflection of 
true biological significance related to adult cardiomyocytes.  
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4.1.3 Limitations 
 
4.1.3.1 Inconsistent iPSC-CMs limit reproducibility  
 
The consistency of iPSC-CMs is important for reproducibility and therefore 
drawing meaningful conclusions. It is difficult to determine if experimental 
results using iPSC-CMs are due to the properties of the lot of cells, or are due 
to a biological property consistent across all iPSC-CM lines and native human 
cardiomyocytes. This variability affects ion-channel expression and response to 
ion-channel modulators [207], [222]. For this reason, it may be good practice to 
use iPSC-CMs from multiple sources, e.g., from different companies, patients, 
or labs in any study. The consequence of this is that more trials on different lines 
would need to be performed, making automated and high-throughput assays 
more critical.  
 
The issue of variability between different iPSC-CM lots/sources was notable in 
this work, as the cells used for the work described in Chapter 2 were 
phenotypically different from the cells used for the work described in Chapter 3. 
Since the cells were purchased from a company and the company aims to 
produce the best quality iPSC-CM, the differentiation and maturation protocols 
have also evolved over time and we were unable to keep a consistent lot, nor 
were different lots derived with the same protocol. The cells from Chapter 3 
were purchased about a year after the cells from Chapter 2. In addition, the 
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differentiation protocol is not public, nor is the composition of the media, both of 
which can have a significant effect on iPSC-CM behavior [9], [223]. Comparing 
the characteristics of the cells from Chapter 2 and Chapter 3, the pre-stimulation 
potential of the cells in Chapter 2 are more depolarized (-64.6 ± 4.4 mV versus 
-71.1 ± 1.7 mV) and the APD90 of the cells in Chapter 2 are shorter (254.1 ± 
30.1 msec versus 338.7 ± 20.0 msec) (Table 3.2 and Appendix A13). Figure 4.3 
also illustrates spontaneous events from the cells from Chapter 2 (Figure 4.3A, 
n = 12) and Chapter 3 (Figure 4.3B, n = 14). The spontaneous events of Chapter 
3 are also more hyperpolarized, the upstroke velocity is noticeably faster and 
the morphology is less rounded than the spontaneous events from the iPSC-
CMs used in Chapter 2. Figure 4.3C quantifies the average and SEM of AP 
characteristics. The impact of adding IK1 is dampened in the more 
hyperpolarized iPSC-CMs of Chapter 3. The electrophysiological differences 
observed between the cells used in Chapter 2 and 3 makes it difficult to compare 
the results of the two chapters because those differences suggest that these 
cells are phenotypically different. Improved consistency of iPSC-CMs would 
make the in vitro model more robust for drug-screening applications. It is 
unreliable to draw reproducible scientific conclusions about adult cardiomyocyte 
behavior if it is obscured by the inherent variability of the in vitro model or if the 
result can only be produced with specific iPSC-CM lines.  
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Figure 4.3: Spontaneous events in cells from Chapter 2 and Chapter 3 
Example spontaneous event from 12 different cells from Chapter 2 experiments 
(A). Example spontaneous event from 14 different cells from Chapter 3 
experiments (B). (C) Average ± SEM of AP characteristics.  
  
 Chapter 2 Chapter 3 
Pre-Stimulation 
Potential (mV) 
-61.5 ± 2.4 -69 ± 1.8 
APD90 (msec) 364.0 ± 50.7 305.7 ± 21.8 
Triangulation (msec) 107.8 ± 35.9 46.14 ± 5.7 
Fraction of 
Repolarization 
0.41 ± 0.05 0.31 ± 0.03 
C 
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4.1.3.2 Spontaneous activity affects AP analysis 
 
If spontaneous events occur prior to the stimulated event, it can alter the 
measured AP characteristics of the analyzed stimulated AP. The presence of 
spontaneous activity makes it difficult to truly compare between conditions. In 
Chapter 2, cells were omitted from the analysis of AP characteristics if they 
contained more than one spontaneous event under EDC or ODC. In Chapter 3, 
we were unable to apply the same selection criteria as in Chapter 2 because all 
trials had spontaneous events during some portion of the protocol so the trials 
used for analysis were affected by the presence of spontaneous activity.  
 
Calcium is an important co-factor for many enzymes, including kinases that are 
responsible for the phosphorylation of ion channels. The inappropriate 
spontaneous release of calcium underlying spontaneous action potentials may 
affect the baseline state of the cell and yield results that are a consequence of 
the immature calcium handling properties. If the rate of spontaneous activity is 
also different between cells, then the degree of the effect of spontaneous 
calcium release may increase the heterogeneity of responses between cells. 
Another possibility is that the consistent spontaneous release of calcium can 
activate pumps and exchangers (e.g., Na+-Ca2+ exchanger) and affect the 
intracellular ionic composition. The caveat of choosing non-spontaneously 
active cells for experiments is that it is difficult to determine if the chosen cell 
was successfully differentiated into a cardiomyocyte. The spontaneously active 
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cells provide reassurance that the chosen cell had differentiated into a 
cardiomyocyte, even though it is an immature one.  
 
4.1.3.3 Immaturity of iPSC-CM is not as simple as supplementing the 
missing IK1 
 
Much attention given to IK1 as a marker for immaturity, because it is not 
expressed in fetal cardiomyocytes and because of its role to establish the 
resting membrane potential and in repolarization during an action potential. 
Reintroduction of IK1 has been shown to improve AP characteristic markers to 
more resemble adult cardiomyocytes. But it is important to remember that 
reduced IK1 expression is not a cause of immaturity but a symptom of it. The 
delicate interconnectedness between protein transcription, expression, 
activation limits the use of iPSC-CMs as a model. To give an idea of the 
complexity, with respect to IK1, iPSC-CMs have reduced expression of KCNJ2, 
the gene that encodes for IK1 [198]. In native adult cardiomyocytes, Kir2.1 
interacts with NaV1.5 (channel that contributes to INa) in a complex along with 
other proteins (not all have been identified) and reciprocally regulate expression 
and function [224]. IK1 expression has also been associated with high 
intracellular calcium and calmodulin kinase II activity [225], [226]. Parts of this 
mechanism is regulated by lipids, including phosphoinositide 4, 5-biphosphate 
and cholesterol [227], [228]. Also, IK1 is regulated by protein kinases A, B and C 
signaling [229]–[231]. Because of the interplay between IK1 and a myriad of 
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different components, it is unknown if reduced IK1 is a symptom of a more 
important issue, or itself is an important contributor to the abnormal phenotype 
of IK1. It is difficult to determine what is important to “fix” in iPSC-CMs to yield a 
suitable in vitro cardiomyocyte model. Nevertheless, we started with IK1 because 
of its decreased expression in iPSC-CMs and its important contribution to the 
AP morphology. 
 
Given the myriad of differences between adult cardiomyocytes and iPSC-CMs, 
careful consideration needs to be taken to how iPSC-CMs are being used as a 
model. For example, when looking at calcium-dependent or -related processes, 
it would be important to note that there is spontaneous calcium release, the ICaL 
and CICR is not as well coordinated, there are less mitochondria, which also 
contributes to Ca2+ uptake and release, and the lack of T-tubules decreases the 
coordination of Ca2+ channel activation throughout the entire cell. IK1 is important 
to adult cardiomyocyte electrophysiology, but injecting IK1 alone may not be 
enough to fully make iPSC-CM electrophysiology equivalent to that of an adult. 
Achieving maturity in iPSC-CMs will be valuable, even if dynamic clamp is still 
needed to “correct” some aspects of the electrophysiology. 
 
4.1.3.4 Selection bias of experiments 
 
As previously noted, there is a selection bias towards spontaneously active 
cells. Another issue, especially in Chapter 3, is that because the protocol is very 
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long, this selects for cells that can survive being patched for extended periods 
of time. In addition, there may have been cells that expired during the protocol 
because it may have a higher reliance on the current that is being affected by 
the ion-channel modulator. It is difficult to determine why some cells were 
unable to undergo the full protocol (unless it was from a technical issue), but the 
long and arduous protocol also introduces a selection bias of the types of iPSC-
CMs. 
 
4.2 Future Directions 
 
4.2.1 Fully-optical dynamic clamp 
 
To realize the ideal fully-optical high-throughput ODC platform, the membrane 
potential must also be measured through optical means, making the need for 
an electrode obsolete. As discussed in Chapter 2 (Section 2.4.3), optogenetics 
could be used to generate a current composed of the ionic species of interest 
to preserve intracellular contents and to be able to observe downstream 
consequences of activation of the ionic current of interest. Even though there 
are many potential advantages to the ODC platform, an optical voltage reporter 
is needed to make this platform practically implementable for research. There 
are several options for choosing an optical readout of membrane potential: 
genetically-encoded voltage indicators (GEVI), and voltage sensitive dyes 
(VSD). However, there are several obstacles to realizing the fully-optical form 
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of ODC. On a practical level, RTXI, the software used to execute the 
experiments described in this thesis, is currently not developed to obtain optical 
information from a camera for real time feedback during experiments, such that 
we are unable to execute the closed-loop system between the LED and the 
optical measurement of Vm, which is necessary for dynamic clamp. Once this is 
achieved, the potential of the fully ODC system can enable more flexible 
formats.  
 
4.2.1.1 Optical tools to read membrane potential  
 
The ideal optical tool (i.e., GEVI, and VSD) would provide the absolute 
membrane potential, respond to changes in membrane potential quickly, and 
provide high temporal resolution. However, fluorescent indicators yield noisy 
data, which would affect the calculation of Itarget. All the options available only 
report the relative membrane potential, where the current dynamic clamp setup 
requires absolute values to calculate the target current. One possible 
hypothetical way to overcome this is to create some sort of calibration or table-
lookup protocol such that the relative fluorescent data could be converted into 
absolute values, but how this can be done, or if it is feasible, is unclear.  
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4.2.2 Enabling dynamic clamp in expanded cell formats  
 
Because the ODC platform opsins can be expressed in and generate a current 
in multiple cells, the idea of expanding the cell formats had been eluded to 
throughout the thesis. The first step towards this is to establish the full ODC 
platform in single cells before transitioning to other formats. With the continued 
development and optimization of automated patch clamp systems, dynamic 
clamp can be run in a more high-throughput manner using single iPSC-CMs 
[102]. The advantage of the ODC method is that it enables dynamic clamp within 
clusters and monolayers. As discussed in Chapters 2 (Section 2.4.2), first, 
iPSC-CMs in more tissue-like preparations are more mature and relevant to 
arrhythmia compared to single cells. Second, the ODC platform would also be 
compatible with co-culturing. There are several cell types in the heart that 
directly impact cardiomyocyte function, including endothelial cells and cardiac 
fibroblasts. In vivo, signals from neighboring cells directly impact cardiomyocyte 
function and co-culturing has been shown to improve maturity and better reflect 
adult cardiomyocyte behavior. For example, more 3D vascularized tissues had 
a different doxorubicin toxicity response than 2D monolayers [205]. In addition 
co-culturing promoted maturity markers and improved response to chronotropic 
drugs [206], [232]. The application of ODC to these more tissue-like platforms 
can enable more electrophysiological investigations into the effects of 
perturbing different currents by various degrees or in specified locations. 
Dynamic clamp with traditional whole-cell patch clamp is limited to single cells, 
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which are useful when studying dynamics on a unit level, but in terms studying 
of cardiac arrhythmia which occurs on a multicellular level, it is difficult to 
extrapolate the behavior from a single cell unit to interconnected tissues. By 
expanding the use of dynamic clamp to multicellular platforms, ODC can enable 
further mechanistic studies to identify therapeutic targets or simulate different 
disease states to test the efficacy and safety of drug candidates.  
 
4.3 Conclusion 
 
This thesis presented how we dynamically activated ArchT to generate a 
specified IArchT current in iPSC-CMs. This takes the first proof-of-principle step 
towards the establishment of the optically-controlled dynamic clamp technique. 
This work serves as a proof-of-principle that demonstrates that fine-tuned 
control of optogenetic proteins can be gained for temporal activation.  
 
In Chapter 2, we were able to implement this dynamic control of ArchT in iPSC-
CMs to inject a target current that mimicked IK1, demonstrating its potential to 
replace an electrode, with the goal of developing a fully-optical dynamic clamp 
platform. In Chapter 3, we aimed to demonstrate an advantage of dynamic 
clamp for drug screening and to demonstrate that the ArchT-based ODC 
platform would perform similarly to the electrode-based EDC platform during 
drug screening. Unfortunately, we were unable to demonstrate an advantage of 
using dynamic clamp, as the ODC platform yielded similar changes in AP 
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morphology as EDC, but did not consistently replicate the resulting APs of EDC. 
This is most likely due to the strong presence of spontaneous activity during the 
experiments, which obscured the interpretation of AP characteristics. The cells 
of Chapter 2 did not have this problem because the cells were phenotypically 
different than those of Chapter 3, most likely due to: (1) lot-to-lot variation, (2) 
the protocol was shorter, and (3) spontaneous activity was not as prominent 
during trials. Moving forward, patching cells without spontaneous activity would 
be ideal; however, this would require the presence of another marker to give the 
experimentalist the ability to select fully-differentiated cardiomyocytes (i.e., in 
lieu of the spontaneity criterion). In addition, the long protocol used in Chapter 
3 also creates another selection bias of cells – i.e., those that are able to survive 
the protocol and being patched for that duration.  
 
The fully-optical dynamic-clamp platform would replace the need for whole-cell 
patch clamp and thus increases the success rate of these drug-screening 
experiments. Because the fully-optical dynamic clamp platform would be free of 
the restrictions that are inherent to whole-cell patch clamp, the fully ODC 
platform could be applied to multi-cellular formats that are not exclusive to just 
cardiomyocytes. If the potential of the fully optogenetic dynamic clamp platform 
is reached, it could become a powerful research tool that pushes the frontiers 
of what can be achieved with dynamic clamp.  
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APPENDIX 
 
 
Appendix A1: Successful ArchT-eGFP expression in iPSC-CMs 
Visualization of eGFP expression following the transfection protocol by Ambrosi 
and Entcheva (2014). (A) displays brightfield image of iPSC-CM beating 
clusters at 40x. (B) displays the corresponding image of eGFP fluorescence at 
40x. 
 
A B 
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Appendix A2: Representative examples of calibration protocol outputs 
The calibration protocol (A) can yield a variety of current outputs (B-D) that may 
be interrupted by repetitive large inward currents (C, D). These inward currents 
are associated with spontaneous contractions (C, D) which in some cases are 
suppressed with ArchT activation (D). 
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Appendix A3: Decrease in spontaneous activity with ODC.  
Average number of spontaneous events occurring during sequence of 10 
stimulated APs at 0.5 Hz pacing. Each point represents a different cell and the 
lines connect the results from the same cell.  
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Appendix A4: Difference in pre-stimulation potential between EDC and 
ODC does not correlate with differences in AP morphology characteristics 
between EDC and ODC 
(A) Difference in pre-stimulation potential on difference in fraction of 
repolarization time. Results at 0.5 Hz, 1 Hz and 2 Hz pacing are purple, green, 
and red, respectively. 
(B) Difference in pre-stimulation potential on difference in triangulation. Results 
at 0.5 Hz, 1 Hz and 2 Hz pacing are purple, green, and red, respectively. 
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Appendix A5:  Amount of current decay during constant-intensity light 
pulses does not correlate with the difference in pre-stimulation potential 
between EDC and ODC 
The amount of current decay was measured as an average difference between 
the initial current and the final current during the three constant-intensity (0.5 
mW/mm2) light pulses during the calibration protocol. The amount of current 
decay was compared to the average difference in pre-stimulation potential (mV) 
between EDC and ODC at (A) 0.5 Hz, (B) 1 Hz, and (C) 2 Hz. Each point 
represents a different cell. 
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Appendix A6: Entire trace of 10 paced APs demonstrating the results of 
the EDC and ODC platforms from example cells  
Results from example cell 1 (A) and cell 10 (B) showing the effects of adding IK1 
while paced 10 times at 3 different frequencies: 0.5 Hz (top), 1 Hz (middle), 2 
Hz (bottom). The gray, orange and green traces represent the control without 
any current addition, adding Itarget with EDC, and adding Itarget with ODC, 
respectively. For each pacing rate, the top panel overlays the 10 paced AP 
traces over time under control and both dynamic-clamp conditions, and the 
black triangles indicate when a stimulus current was delivered. In the middle 
panel, the traces give the calculated target currents for EDC and ODC. The 
bottom panel shows the calculated light intensity used to generate the target 
current. The filled black triangles indicate when a stimulus current was delivered 
and provides a reference to which of the 10 paced APs in Figures 3 (A) and 4 
(B) are displayed. 
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Appendix A7: Representative example of a large undershoot after an AP 
and how EDC is able to compensate for the undershoot 
Example cell (cell 3) showing the effects of adding IK1 while paced 10 times at 
3 different frequencies: (A, B) 0.5 Hz, (C, D) 1 Hz, (E, F) 2 Hz. The gray, orange 
and green traces represent the control without any current addition, adding Itarget 
with EDC, and adding Itarget with ODC, respectively. The top panels overlay the 
10 paced AP traces under control and both dynamic-clamp conditions, and the 
black triangles indicate when a stimulus current was delivered. In the middle 
panels, the traces give the calculated target currents for EDC and ODC. The 
bottom panels show the calculated light intensity used to generate the target 
current with ODC. The filled black triangles in the top panels (A, C, E) provide a 
reference for zoomed portions shown in B, D, and F, respectively.  
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Appendix A8: Summary of the effects of EDC or ODC on AP morphology 
at different pacing frequencies  
Pre-stimulation potential (left), fraction of repolarization (middle) and 
triangulation (right) of individual cells at 0.5 Hz (A) and 1 Hz (B) pacing in control 
(gray) and after adding an IK1 target current via EDC (orange) or ODC (green). 
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Appendix A9: Entire trace of 10 paced APs demonstrating the results of 
the EDC and ODC platforms from example cell with E-4031 addition 
Results from example cell 13 showing the effects of adding IK1 while paced 10 
times at 0.5 Hz. The figure is organized in the same manner as Appendix A6. 
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Appendix A10: In silico model prediction shows that the error between 
RTXI and the amplifier has limited impact on dynamic clamp experiments 
To predict the effects on dynamic clamp performance of the 5% error between 
the membrane potential measured by the amplifier versus the membrane 
potential reported by RTXI, we used an in silico approach, simulating IK1 
dynamic clamp injection into an iPSC-CM computational model (Paci et al., 
(2013)). We used the same equations for IK1 as in our experiments and clamped 
intracellular [Na+] to mimic a patched cell. The dynamically clamped iPSC-CM 
model was run for 810 beats at a 1 Hz pacing rate with and without the amplifier 
calibration error and the last 10 APs were analyzed. (A) The top panel illustrates 
the last AP waveform with (dashed purple trace) and without (blue trace) the 
error. The bottom panel shows the corresponding target IK1. The presence of 
the calibration error leads to an overestimation of this current during phase 4 of 
the AP, causing a small (about 2 mV) hyperpolarization of the resting membrane 
potential. (B) The resulting AP characteristics with and without the calibration 
error are very close, with about a 3% change in APD90. Importantly, the 
predicted effect of the calibration error calculated here does not depend on how 
the dynamic clamp target current is added to the cell and is therefore expected 
to affect Itarget calculated by the EDC and ODC systems equally. 
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Appendix A11: In silico model predicting the effect of activation and 
deactivation kinetics on dynamic clamp performance and experimentally 
measured ArchT time constants 
(A) To test that the kinetics of ArchT are not prohibitively slow for dynamic 
clamp, we simulated our ODC platform using the Paci et al. (2013) iPSC-CM 
model with an added ArchT model having a single time constant for activation 
and deactivation. We varied this time constant to see how large of a delay could 
be tolerated. The ArchT current generated with different time constants are 
displayed in the panel above and sthe resulting stimulated APs are in the panel 
below. (B) Experimentally measured time constants of activation of ArchT in 
each cell. 
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Appendix A12: Measuring stability of ArchT illumination during a voltage 
clamp and light clamp protocol  
(A) The top panel shows the light clamp protocol and the bottom panel shows 
the voltage clamp protocol. This protocol was cycled through repeatedly to 
measure IArchT over time and at different holding potentials. (B) Results from a 
representative cell showing IArchT produced at different times of the protocol and 
at different holding potentials.   
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Appendix A13: AP morphology characteristics  
The average and SEM of pre-stimulation potential (PSP) (mV), overshoot (mV), 
and APD90 (msec) without dynamic clamp, with EDC and with ODC. The 
characteristics after E-4031 addition are also listed.  
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